UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign
Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For
the month of December 2015
Commission File Number
000-28508
Flamel
Technologies S.A.
(Translation of registrant's
name into English)
Parc Club du Moulin
à Vent
33 avenue du Dr. Georges
Levy
69200 Vénissieux
France
(Address of principal
executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Indicate by check mark whether registrant
by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule
12g3-2(b) under the Securities Exchange Act of 1934.
If "Yes"
is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-____________
Index
FLAMEL TECHNOLOGIES
S.A.
FLAMEL TECHNOLOGIES
S.A.
Condensed Consolidated
Statements of Operations
(Unaudited)
(Amounts
in thousands of dollars, except per share data)
| |
Three months ended June 30, | |
| |
2014 | | |
2015 | |
Revenue: | |
| | | |
| | |
License and research revenue | |
$ | 1,819 | | |
| - | |
Product sales and services | |
| 2,499 | | |
$ | 49,795 | |
Total revenue | |
| 4,318 | | |
| 49,795 | |
Costs and expenses: | |
| | | |
| | |
Cost of goods and services sold | |
| (507 | ) | |
| (2,756 | ) |
Research and development | |
| (3,600 | ) | |
| (7,204 | ) |
Selling, general and administrative | |
| (4,065 | ) | |
| (5,873 | ) |
Fair value remeasurement of acquisition liabilities, with related parties | |
| (12,607 | ) | |
| (32,000 | ) |
Amortisation of intangible R&D assets | |
| (2,938 | ) | |
| (3,139 | ) |
Total | |
| (23,717 | ) | |
| (50,972 | ) |
| |
| | | |
| | |
Operating profit (loss) | |
| (19,399 | ) | |
| (1,177 | ) |
| |
| | | |
| | |
Net interest income (expense) | |
| 123 | | |
| 310 | |
Interest expense on debt related to the royalty agreement with related parties | |
| (1,079 | ) | |
| (2,726 | ) |
Foreign exchange gain (loss) | |
| 292 | | |
| (3,565 | ) |
| |
| | | |
| | |
Income (loss) before income taxes | |
| (20,063 | ) | |
| (7,158 | ) |
Income tax benefit (expense) | |
| (137 | ) | |
| (10,242 | ) |
Net income (loss) from continuing operations | |
$ | (20,200 | ) | |
$ | (17,400 | ) |
Net income (loss) from discontinued operations | |
$ | (873 | ) | |
$ | 0 | |
Net income (loss) | |
$ | (21,073 | ) | |
$ | (17,400 | ) |
| |
| | | |
| | |
Earnings (loss) per ordinary share (Basic and Diluted) | |
| | | |
| | |
| |
| | | |
| | |
Continuing operations | |
$ | (0.53 | ) | |
$ | (0.43 | ) |
Discontinued operations | |
$ | (0.02 | ) | |
$ | 0.00 | |
Net income (loss) | |
$ | (0.55 | ) | |
$ | (0.43 | ) |
| |
| | | |
| | |
Weighted average number of shares outstanding (in thousands) : | |
| | | |
| | |
| |
| | | |
| | |
Basic | |
| 38,438 | | |
| 40,353 | |
Diluted | |
| 38,438 | | |
| 40,353 | |
See
notes to condensed consolidated financial statements
FLAMEL TECHNOLOGIES
S.A.
Condensed Consolidated
Statements of Operations
(Unaudited)
(Amounts
in thousands of dollars, except per share data)
| |
Six months ended June 30, | |
| |
2014 | | |
2015 | |
Revenue: | |
| | | |
| | |
License and research revenue | |
$ | 2,417 | | |
$ | 0 | |
Product sales and services | |
| 6,479 | | |
| 82,521 | |
Total revenue | |
| 8,896 | | |
| 82,521 | |
Costs and expenses: | |
| | | |
| | |
Cost of goods and services sold | |
| (1,280 | ) | |
| (6,386 | ) |
Research and development | |
| (7,544 | ) | |
| (13,226 | ) |
Selling, general and administrative | |
| (7,581 | ) | |
| (10,336 | ) |
Fair value remeasurement of acquisition liabilities, with related parties | |
| (27,233 | ) | |
| (37,254 | ) |
Amortisation of intangible R&D assets | |
| (5,875 | ) | |
| (6,282 | ) |
Acquisition note expenses with related parties | |
| (3,013 | ) | |
| - | |
Total | |
| (52,526 | ) | |
| (73,484 | ) |
| |
| | | |
| | |
Operating profit (loss) | |
| (43,630 | ) | |
| 9,037 | |
| |
| | | |
| | |
Net interest income (expense) | |
| 220 | | |
| 1,456 | |
Interest expense | |
| (5,552 | ) | |
| (482 | ) |
Interest expense on debt related to the royalty agreement with related parties | |
| (1,235 | ) | |
| (2,985 | ) |
Foreign exchange gain (loss) | |
| 471 | | |
| 7,936 | |
| |
| | | |
| | |
Income (loss) before income taxes | |
| (49,726 | ) | |
| 14,962 | |
Income tax benefit (expense) | |
| 2,665 | | |
| (20,715 | ) |
Net income (loss) from continuing operations | |
| (47,061 | ) | |
| (5,753 | ) |
Net income (loss) from discontinued operations | |
$ | (650 | ) | |
$ | 0 | |
Net income (loss) | |
$ | (47,711 | ) | |
$ | (5,753 | ) |
| |
| | | |
| | |
Earnings (loss) per ordinary share (Basic and Diluted) | |
| | | |
| | |
| |
| | | |
| | |
Continuing operations | |
$ | (1.41 | ) | |
$ | (0.14 | ) |
Discontinued operations | |
$ | (0.02 | ) | |
$ | 0.00 | |
Net income (loss) | |
$ | (1.43 | ) | |
$ | (0.14 | ) |
| |
| | | |
| | |
Weighted average number of shares outstanding (in thousands) : | |
| | | |
| | |
| |
| | | |
| | |
Basic | |
| 33,403 | | |
| 40,281 | |
Diluted | |
| 33,403 | | |
| 40,281 | |
See
notes to condensed consolidated financial statements
Condensed Consolidated
Statements of Comprehensive Income (Loss)
(Unaudited)
(Amounts in thousands of
dollars)
| |
Three months ended June 30, | |
| |
2014 | | |
2015 | |
| |
| | |
| |
Net Income (loss) | |
$ | (21,073 | ) | |
$ | (17,400 | ) |
Other comprehensive income (loss): | |
| | | |
| | |
Net foreign currency translation gain (loss) | |
| (1,257 | ) | |
| 5,262 | |
Unrealized gain (loss) on marketable Securities | |
| - | | |
| (356 | ) |
Other comprehensive income (loss), net of tax | |
| (1,257 | ) | |
| 4,906 | |
Comprehensive Income (loss) | |
$ | (22,330 | ) | |
$ | (12,494 | ) |
| |
Six months ended June 30, | |
| |
2014 | | |
2015 | |
| |
| | |
| |
Net Income (loss) | |
$ | (47,711 | ) | |
$ | (5,753 | ) |
Other comprehensive income (loss): | |
| | | |
| | |
Net foreign currency translation gain (loss) | |
| (2,025 | ) | |
| (11,387 | ) |
Unrealized gain (loss) on marketable Securities | |
| - | | |
| - | |
Other comprehensive income (loss), net of tax | |
| (2,025 | ) | |
| (11,387 | ) |
Comprehensive Income (loss) | |
$ | (49,736 | ) | |
$ | (17,140 | ) |
See notes to condensed
consolidated financial statements
Condensed Consolidated
Balance Sheets
(Unaudited)
(Amounts in thousands of
dollars, except per share data)
| |
December 31, 2014 | | |
June 30, 2015 | |
ASSETS | |
| | | |
| | |
Current assets: | |
| | | |
| | |
Cash and cash equivalents | |
$ | 39,760 | | |
$ | 55,236 | |
Marketable securities | |
| 53,074 | | |
| 60,884 | |
Accounts receivable (net of allowance of $127 and $118 at December 31, 2014, and June 30, 2015 respectively) | |
| 1,679 | | |
| 3,498 | |
Inventory | |
| 6,729 | | |
| 5,751 | |
Research and development tax credit receivable | |
| 5,932 | | |
| 1,609 | |
Prepaid expenses and other current assets | |
| 4,418 | | |
| 5,189 | |
Total current assets from continuing operations | |
| 111,592 | | |
| 132,167 | |
Total current assets from assets held for sale | |
| 730 | | |
| - | |
| |
| | | |
| | |
Goodwill, net | |
| 18,491 | | |
| 18,491 | |
Property and equipment, net | |
| 1,776 | | |
| 1,978 | |
Intangible assets | |
| 28,389 | | |
| 22,107 | |
Other assets: | |
| | | |
| | |
Income tax deferred charge | |
| 13,102 | | |
| 11,685 | |
Other long-term assets | |
| 125 | | |
| 117 | |
Total long term assets from continuing operations | |
| 61,883 | | |
| 54,378 | |
Total assets including "assets held for sale" | |
$ | 174,205 | | |
$ | 186,545 | |
| |
| | | |
| | |
LIABILITIES | |
| | | |
| | |
Current liabilities: | |
| | | |
| | |
Current portion of long-term debt, incl to related parties | |
$ | 42,332 | | |
$ | 37,803 | |
Accounts payable | |
| 8,024 | | |
| 11,403 | |
Deferred revenue | |
| 1,336 | | |
| 21 | |
Accrued expenses | |
| 5,667 | | |
| 3,096 | |
Other current liabilities | |
| 5,672 | | |
| 349 | |
Income tax payable | |
| 7,643 | | |
| 77 | |
Total current liabilities from continuing operations | |
| 70,674 | | |
| 52,749 | |
Total current liabilities from liabilities held for sale | |
| 168 | | |
| - | |
| |
| | | |
| | |
Long-term debt, less current portion, incl. to related parties | |
| 76,135 | | |
| 111,882 | |
| |
| | | |
| | |
Deferred tax liabilities | |
| - | | |
| 6,071 | |
Other long-term liabilities | |
| 2,333 | | |
| 2,206 | |
Total long-term liabilities from continuing operations | |
| 78,468 | | |
| 120,159 | |
| |
| | | |
| | |
Shareholders' equity: | |
| | | |
| | |
Ordinary shares: 40,191,264 issued and outstanding at December 31, 2014 and 40,498,764 at June 30, 2015 (shares authorised 52,549,354) at nominal value of 0.122 euro | |
| 6,188 | | |
| 6,229 | |
Additional paid-in capital | |
| 346,582 | | |
| 352,423 | |
Accumulated deficit | |
| (320,452 | ) | |
| (326,205 | ) |
Accumulated other comprehensive income (loss) | |
| (7,423 | ) | |
| (18,810 | ) |
Total shareholders' equity | |
| 24,895 | | |
| 13,637 | |
Total liabilities and shareholders' equity including held for sale | |
$ | 174,205 | | |
$ | 186,545 | |
See notes to condensed
consolidated financial statements
FLAMEL TECHNOLOGIES
S.A.
Condensed Consolidated
Statements of Cash Flows
(Unaudited)
| |
Six months ended June 30, | |
| |
2014 | | |
2015 | |
| |
| | |
| |
Cash flows from operating activities: | |
| | | |
| | |
Net income (loss) | |
$ | (47,711 | ) | |
$ | (5,753 | ) |
Depreciation of property and equipment and intangible assets | |
| 7,216 | | |
| 6,531 | |
Gains on sales of marketable securities | |
| - | | |
| 225 | |
Grants recognized in other income and income from operations | |
| (337 | ) | |
| (1,086 | ) |
Remeasurement of acquisition liabilities | |
| 30,246 | | |
| 37,256 | |
Interest expenses on debt related to the royalty agreement including related party | |
| 1,179 | | |
| 2,986 | |
Unrealized exchange gains | |
| - | | |
| (7,315 | ) |
Stock compensation expense | |
| 1,107 | | |
| 4,152 | |
Income tax | |
| (2,807 | ) | |
| 6,456 | |
Increase (decrease) in cash from: | |
| | | |
| | |
Accounts receivable | |
| 2,520 | | |
| (1,015 | ) |
Inventory | |
| (1,816 | ) | |
| 1,175 | |
Prepaid expenses and other current assets | |
| (750 | ) | |
| (1,460 | ) |
Research and development tax credit receivable | |
| 5,132 | | |
| 3,807 | |
Accounts payable and Other Current Liabilities | |
| 214 | | |
| (3,265 | ) |
Deferred revenue | |
| (397 | ) | |
| (1,314 | ) |
Accrued expenses | |
| (1,847 | ) | |
| (2,138 | ) |
Other long-term assets and liabilities | |
| 248 | | |
| 59 | |
Net cash provided by (used in) operating activities | |
| (7,803 | ) | |
| 39,301 | |
| |
| | | |
| | |
Cash flows from investing activities: | |
| | | |
| | |
Purchases of property and equipment | |
| (712 | ) | |
| (659 | ) |
Purchase of marketable securities | |
| (27,752 | ) | |
| (31,093 | ) |
Proceeds from sales of marketable securities | |
| 4,334 | | |
| 21,196 | |
Net cash provided by (used in) investing activities | |
| (24,130 | ) | |
| (10,556 | ) |
| |
| | | |
| | |
Cash flows from financing activities: | |
| | | |
| | |
Repayment of Debt | |
| (34,471 | ) | |
| (5,791 | ) |
Reimbursment of conditional grants | |
| (151 | ) | |
| (615 | ) |
Earnout payments on acquisition related debt to related parties | |
| (611 | ) | |
| (6,118 | ) |
Proceeds from issuance of ordinary shares and warrants | |
| 116,152 | | |
| 1,652 | |
Net cash provided by (used in) financing activities | |
| 80,919 | | |
| (10,872 | ) |
| |
| | | |
| | |
Effect of exchange rate changes on cash and cash equivalents | |
| (1,518 | ) | |
| (2,397 | ) |
| |
| | | |
| | |
Net increase (decrease) in cash and cash equivalents | |
| 47,468 | | |
| 15,476 | |
| |
| | | |
| | |
Cash and cash equivalents, beginning of period | |
| 6,636 | | |
| 39,760 | |
| |
| | | |
| | |
Cash and cash equivalents, end of period | |
$ | 54,104 | | |
$ | 55,236 | |
| |
| | | |
| | |
Supplemental disclosures of cash flow information: | |
| | | |
| | |
Income tax paid | |
| 281 | | |
| 20,875 | |
Interest paid | |
| 5,358 | | |
| 1,367 | |
See
notes to condensed consolidated financial statements
FLAMEL TECHNOLOGIES
S.A.
Consolidated
Statements of Shareholders’ Equity (Unaudited)
(Amounts
in thousands of dollars)
| |
Ordinary Shares | | |
Additional
Paid-in | | |
Accumulated | | |
Accumulated Other
Comprehensive | | |
Shareholders' | |
| |
Shares | | |
Amount | | |
Capital | | |
Deficit | | |
Income (Loss) | | |
Equity | |
| |
| | |
| | |
| | |
| | |
| | |
| |
Balance at
January 1, 2015 | |
| 40,191,264 | | |
$ | 6,188 | | |
$ | 346,581 | | |
$ | (320,452 | ) | |
$ | (7,423 | ) | |
$ | 24,894 | |
Subscription of warrants | |
| | | |
| | | |
| | | |
| | | |
| | | |
| - | |
Issuance of ordinary shares on exercise of stock
or warrants | |
| 307,500 | | |
| 41 | | |
| 1,611 | | |
| | | |
| | | |
| 1,652 | |
Issuance of ordinary shares on Capital Raise | |
| - | | |
| - | | |
| - | | |
| | | |
| | | |
| - | |
Stock-based compensation expense | |
| | | |
| | | |
| 4,231 | | |
| | | |
| | | |
| 4,231 | |
Net loss | |
| | | |
| | | |
| | | |
| (5,753 | ) | |
| | | |
| (5,753 | ) |
Other comprehensive income
(loss) | |
| | | |
| | | |
| | | |
| | | |
| (11,387 | ) | |
| (11,387 | ) |
Balance at June 30, 2015 | |
| 40,498,764 | | |
$ | 6,229 | | |
$ | 352,423 | | |
$ | (326,205 | ) | |
$ | (18,810 | ) | |
$ | 13,637 | |
| |
Ordinary Shares | | |
Additional
Paid-in | | |
Accumulated | | |
Accumulated Other
Comprehensive | | |
Shareholders' | |
| |
Shares | | |
Amount | | |
Capital | | |
Deficit | | |
Income (Loss) | | |
Equity | |
Balance at March
31, 2015 | |
| 40,253,014 | | |
$ | 6,196 | | |
$ | 348,571 | | |
$ | (308,805 | ) | |
$ | (23,716 | ) | |
| 22,246 | |
Subscription of warrants | |
| | | |
| | | |
| | | |
| | | |
| | | |
| - | |
Issuance of ordinary shares on exercise of stock
or warrants | |
| 245,750 | | |
| 33 | | |
| 1,372 | | |
| | | |
| | | |
| 1,405 | |
Issuance of ordinary shares on Capital Raise | |
| - | | |
| - | | |
| - | | |
| | | |
| | | |
| - | |
Stock-based compensation expense | |
| | | |
| | | |
| 2,480 | | |
| | | |
| | | |
| 2,480 | |
Net loss | |
| | | |
| | | |
| | | |
| (17,400 | ) | |
| | | |
| (17,400 | ) |
Other comprehensive income
(loss) | |
| | | |
| | | |
| | | |
| | | |
| 4,906 | | |
| 4,906 | |
Balance at June 30, 2015 | |
| 40,498,764 | | |
$ | 6,229 | | |
$ | 352,423 | | |
$ | (326,205 | ) | |
$ | (18,810 | ) | |
$ | 13,637 | |
FLAMEL TECHNOLOGIES
S.A.
Notes to Condensed
Consolidated Financial Statements
(Unaudited)
1.
SUMMARY OF SIGNIFICANT accounting policies
In the opinion of the
management of Flamel Technologies S.A. (the “Company”), the accompanying unaudited, condensed, consolidated financial
statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial
statements. Accordingly, these Financial Statements do not include all of the information and footnotes required for complete annual
financial statements, since certain footnotes and other financial information required by generally accepted accounting principles
in the United States (or US GAAP) can be condensed or omitted for interim reporting requirements. In the opinion of management,
all adjustments (consisting of only normal recurring accruals) considered necessary for a fair presentation of our financial position
and operating results have been included.
The preparation of
consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated
financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ
from those estimates.
Operating results for
the six-month ended June 30, 2015 are not necessarily indicative of the results that may be expected for the full year ending December
31, 2015. These condensed consolidated interim financial statements should be read in conjunction with the Company's audited annual
financial statements.
The reporting currency
of the Company and its wholly-owned subsidiaries is the U.S. dollar as permitted by the SEC for a foreign private issuer (S-X Rule
3-20(a)). All financial statement amounts of the Company and any other subsidiary for which the functional currency is the Euro
or any other currency other than the U.S. dollar, are translated into U.S. dollar equivalents at exchange rates as follows: (1)
asset and liability accounts at period-end rates, (2) income statement accounts at weighted average exchange rates for the period-end,
and (3) shareholders' equity accounts at historical rates. Corresponding translation gains or losses are recorded in shareholders'
equity.
The Company followed
the guidance in Financial Accounting Standards Board Accounting Standards Codification (“ASC”) Topic 205 Presentation
of Financial Statements (ASC 205), Topic 360 Property, Plant and Equipment (ASC 360) and Accounting Standards Update (ASU 2014-08),
Reporting of Discontinued Operations and Disclosures of Disposals of Components of an Entity in determining the accounting for
the divestiture of the Pessac facility which occurred on December 1, 2014. Presenting the divestiture as a discontinued operation
provides a better understanding of the results of the Company’s new strategy and in assessing the impact of the disposal
on the ongoing operations of the entity.
The results of discontinued
operations, less income taxes, have been reported as a separate component of income in the statement of operations. The assets
and liabilities of the discontinued operation have been reported separately in the asset and liability section, of the balance
sheets for the periods presented therein. See note 4 below for a description of the facts and circumstances related to the disposal.
Other comprehensive
income includes currency translation adjustments and unrealized gains on marketable securities. For the six-month period ended
June 30, 2015 it represents a loss of $11.4 million.
FLAMEL TECHNOLOGIES
S.A.
Notes to Condensed
Consolidated Financial Statements
(Unaudited)
In May 2014, the FASB
issued ASU 2014-09, “Revenue from Contracts with Customers.” The standard requires an entity to recognize the amount
of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The standard will replace
most existing revenue recognition guidance in U.S. GAAP when it becomes effective and permits the use of either the retrospective
or cumulative effect transition method. The ASU was originally effective for annual and interim periods beginning after December
15, 2016; however, on July 9, 2015, the FASB decided to defer by one year the effective date of the ASU. As a result, the standard
will be effective for annual and interim periods beginning after December 15, 2017. The Company has not yet selected a transition
method and is evaluating the impact the adoption will have on its consolidated financial statements and related disclosures.
2. REVENUES
2.1 Product sales
and services
Revenue is generally
recognized when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the seller’s
price to the buyer is fixed or determinable, and collectability is reasonably assured. The Company records revenue from product
sales when title and risk of ownership have been transferred to the customer, which is typically upon delivery to the customer,
and when the selling price is determinable. As is customary in the pharmaceutical industry, the Company’s gross product sales
are subject to a variety of deductions in arriving at reported net product sales. When the Company recognizes revenue from the
sale of its products, an estimate of provision for sales returns and allowances is recorded which reduces product sales. These
deductions include estimates for product returns, chargebacks, payment discounts and other sales allowances and rebates. The estimate
for chargebacks is determined when product is shipped from the wholesalers to their customers. The return allowance, when estimable,
is based on an analysis of the historical returns of the product or similar products.
For generic products
and branded products sold in mature and stable markets where changes in selling price are rare, the Company recognizes revenues
upon shipment. For branded products where market conditions remain volatile and selling price is subject to change the Company
recognizes revenue based on net product sales of wholesalers to their customers. For new product launches the Company recognizes
revenue once sufficient data is available to determine product acceptance in the marketplace such that product returns may be estimated
based on historical data and there is evidence of reorders and consideration is made of wholesaler inventory levels. Net product
sales of wholesalers to their customers are determined using sales data from an independent wholesaler inventory tracking service.
Net sales of wholesalers to their customers are calculated by deducting estimates for returns for wholesaler customers, chargebacks,
payment discounts and other sales or discounts offered from the applicable gross sales value. Estimates for product returns are
adjusted periodically based upon historical rates of returns, inventory levels in the distribution channel and other related factors.
The Company
recognized net product sales of $82.5 million for the first six-month of 2015 compared to $6.4 million for the six-month
period ended June 30, 2014. Branded product sales are generated on sales from wholesalers to hospitals of
Bloxiverz® and Vazculep®. Net product sales of wholesalers to their customers (hospitals) are
determined using sales data from an independent wholesaler inventory tracking service and are calculated by deducting from
the applicable gross sales value estimates for returns for wholesalers’ customers, chargebacks, early payment
discounts and other sales or discounts offered.
FLAMEL TECHNOLOGIES
S.A.
Notes to Condensed
Consolidated Financial Statements
(Unaudited)
3. RESEARCH TAX CREDIT
The French government
provides tax credits to companies for spending on innovative research and development. The research tax credit is considered as
a grant and is deducted from operating expenses.
For the six-month period
ended June 30, 2015, the credit amounted to $1.6 million ($0.9 million for the three month period ended June 30, 2015) compared
to $2.7 million for the six-month period ended June 30, 2014 ($1.3 million for the three month period ended June 30, 2014). The
decrease reflects the reduction in R&D spending that is deemed eligible for the R&D tax credit in France.
4. DISCONTINUED OPERATIONS
On December 1, 2014,
the Company signed an Asset Purchase Agreement with Recipharm for the divestiture of its development and manufacturing facility
located in Pessac, France.
The assets included
in the divestiture were tangible equipment, furniture and fixtures, inventories and all intellectual property rights relating to
the operation and technological know-how necessary in manufacturing the products that are produced in the facility and the assignment
to Recipharm of all employees, customer contracts and liabilities which primarily relate to agreements of the Company with GlaxoSmithKline
(“GSK”) for the manufacture and sale of Coreg CR®. Coreg CR® was Flamel’s lead
product using the Micropump drug delivery platform that was developed with GSK and has been approved and sold in the US since 2007.
The semi-finished product is manufactured in the Pessac Facility. The contracts assigned to Recipharm exclude the Amended 2003
License Agreement and 2004 License Agreement (collectively “License Agreements”) between Flamel and GSK for the development
of Coreg CR®. However, the royalties to be earned by Flamel from the sales of Coreg CR® were transferred
to Recipharm as part of the Asset Purchase Agreement. All costs and future revenues relating to the manufacture and sale of Coreg
CR® were transferred to Recipharm.
Royalties from Coreg
CR® sales amounted to $3.6 million in the first half of 2014. Revenues from sales of Coreg CR® microparticles
to GSK amounted to $3.5 million in the first half of 2014. Revenues from research revenues with undisclosed partners amounted to
$1.6 million in the first half of 2014.
The aggregate consideration
the company received for the acquired assets and business was $13.2 million, plus the value of acquired inventory. All cash and
receivables pertaining to Pessac Facility business prior to the sale were retained by Flamel. A contribution of $0.7 million was
made to finance potential future retirement indemnities payable on transferred employees. The business was accounted for as a discontinued
operation in the fourth quarter of 2014 and, therefore, the operating results of our Pessac Facility business were included in
Discontinued Operations for the six-month period ended June 30, 2014.
In connection with
the Asset Purchase Agreement, the Company entered into a Master Agreement on Supply and Services of Products (“MSA”).
Recipharm will provide various services in the domain of R&D and manufacture of pharmaceutical products for an initial
non-cancellable period of five years for a minimum amount of services per year and for a cumulative total of $22.5 million. Over
the initial term, any services to be provided to Flamel by Recipharm shall include internal and external costs incurred by Recipharm
plus 20%, which has been determined to be fair value for such services. As of June 30, 2015 for the quarter ended, these services
amounted to $1.1 million and for the six month period amounted to $2.4 million.
FLAMEL TECHNOLOGIES
S.A.
Notes to Condensed
Consolidated Financial Statements
(Unaudited)
Summary results of
operations and major cash-flows for the Pessac business for the six and three month periods ended June 30, 2014 are detailed below.
For the six and three month periods ended June 30, 2015 the Pessac business had no impact on results of operations or cash-flows
other than in relation to contract manufacturing services in accordance with the “MSA” as discussed in the preceding
paragraph :
In thousands of U.S. Dollars | |
Three
months ended June 30, 2014 | | |
Six
months ended
June 30, 2014 | |
| |
| | |
| |
Revenues | |
$ | 4,318 | | |
$ | 8,896 | |
Income (loss) from operations | |
| (873 | ) | |
| (650 | ) |
Income (loss) from discontinued operations, net of tax | |
$ | (873 | ) | |
$ | (650 | ) |
In thousands of U.S. Dollars | |
Three months ended June 30, 2014 | | |
Six months ended June 30, 2014 | |
Capital Expenditures | |
$ | 317 | | |
$ | 631 | |
| |
| | | |
| | |
Depreciation and Amortization | |
| 517 | | |
| 1,033 | |
| |
| | | |
| | |
Operating and investing non-cash elements | |
| (186 | ) | |
| (347 | ) |
5. SHAREHOLDERS'
EQUITY
During the six-month
period ended June 30, 2015, 307,500 shares were issued by the Company as a result of the exercise of stock options and warrants.
The total amount of
shares outstanding as of June 30, 2015 amounted to 40,498,764.
6. STOCK COMPENSATION
EXPENSE AND EARNINGS PER SHARE
During the six-month
period ended June 30, 2015, no stock options, free share awards or warrants were granted by the Company.
Given the net loss
for the three month and six month periods ended June 30, 2015 there were no shares considered to have a dilutive impact for earnings
per share purposes
FLAMEL TECHNOLOGIES
S.A.
Notes to Condensed
Consolidated Financial Statements
(Unaudited)
7. INCOME
TAX
Income (loss)
before income taxes comprises the following for the six-month period ended June 30, 2015:
(in thousands of U.S. dollars) | |
three
months ended June 30, 2015 | | |
six
months ended
June 30, 2015 | |
| |
| | |
| |
Ireland. | |
$ | (11,278 | ) | |
$ | (16,317 | ) |
France. | |
| (1,123 | ) | |
| 9,113 | |
United States.. | |
| 5,242 | | |
| 22,166 | |
Total. | |
$ | (7,159 | ) | |
$ | 14,962 | |
A reconciliation
of income tax benefit (provision) computed at the French statutory rate (33.33%), Irish statutory rate (12.5%) and the US statutory
rate (36.15%) to the actual income tax expense is as follows:
(in thousands of U.S. dollars) | |
Three months ended
June 30, 2015 | | |
Six months ended
June 30, 2015 | |
| |
| | |
| |
Income tax benefit (provision) computed at the statutory rate | |
$ | (115 | ) | |
$ | (9,011 | ) |
Non Taxable remeasurement of fair value accounting of earn out | |
| (11,568 | ) | |
| (13,467 | ) |
Valuation allowance on operating losses in Ireland | |
| (1,410 | ) | |
| (2,040 | ) |
Other temporary and permanent differences | |
| 2,851 | | |
| 3,803 | |
Total | |
$ | (10,242 | ) | |
$ | (20,715 | ) |
In accordance
with ASC 740-270, Interim Reporting, the tax provision for the six months ended June 30, 2015 is computed using an estimated
annual effective tax rate of 31%. This is applied to income before tax, excluding losses from Irish operations, since no benefit
is anticipated to be recognized on net operating loss carry forwards for the current fiscal year and items for which a reliable
estimate cannot be made. The income tax provision as of June 30, 2015 amounts to $20.7 million.
8. INTANGIBLE
ASSETS
| |
December
31, | | |
June
30, | |
| |
2014 | | |
2015 | |
(In thousands
of U.S. dollars) | |
Gross carrying
amount | | |
Accumulated amortization | | |
Impairment | | |
Intangible assets,
net | | |
Gross carrying
amount | | |
Accumulated amortization | | |
Impairment | | |
Intangible assets,
net | |
| |
| | |
| | |
| | |
| | |
| | |
- | | |
| | |
| |
Intangible asset corresponding to acquired IPR&D
of Bloxiverz | |
| 35,248 | | |
| (11,749 | ) | |
| | | |
| 23,499 | | |
| 35,248 | | |
| (17,623 | ) | |
| | | |
| 17,625 | |
Intangible asset corresponding
to acquired IPR&D of Vazculep | |
| 12,061 | | |
| - | | |
| (7,170 | ) | |
| 4,891 | | |
| 12,061 | | |
| (408 | ) | |
| (7,170 | ) | |
| 4,483 | |
Total Intangible assets | |
$ | 47,309 | | |
$ | (11,749 | ) | |
$ | (7,170 | ) | |
$ | 28,390 | | |
$ | 47,309 | | |
$ | (18,031 | ) | |
$ | (7,170 | ) | |
$ | 22,108 | |
Intangible
assets corresponding to acquired in-process R&D of Bloxiverz are being amortized on a straight-line basis over a 3 year period
beginning January 1, 2014. Intangible assets corresponding to acquired in-process R&D of Vazculep are amortized on a straight-line
period over 6-years beginning January 1, 2015.
FLAMEL TECHNOLOGIES
S.A.
Notes to Condensed
Consolidated Financial Statements
(Unaudited)
9. INVENTORY
Inventories
consist of raw materials and finished products, which are stated at cost determined under the first-in, first-out ("FIFO")
method. Raw materials used in the production of pre-clinical and clinical products are expensed as R&D costs when consumed.
The Company establishes reserves for inventory estimated to be obsolete, unmarketable or slow-moving on a case by case basis.
The components
of inventories were as follows:
(In thousands of U.S. dollars) | |
December 31,
2014 | | |
June 30,
2015 | |
| |
| | |
| |
Raw materials | |
$ | 1,661 | | |
$ | 1,860 | |
Finished goods. | |
| 5,068 | | |
| 3,891 | |
| |
| | | |
| | |
Inventories, net | |
$ | 6,729 | | |
$ | 5,751 | |
10. LONG-TERM
DEBT
Long-term
debt comprises:
(In thousands of U.S. dollars) | |
December 31,
2014 | | |
June 30,
2015 | |
| |
| | |
| |
Government loans for R&D projects (a) | |
$ | 3,717 | | |
$ | 1,702 | |
Acquisition liability contingent consideration (b) | |
| 70,112 | | |
| 89,077 | |
Acquisition liability warrant consideration (b) | |
| 34,542 | | |
| 46,713 | |
Deerfield Royalty agreement (c) | |
| 6,837 | | |
| 8,256 | |
Broadfin Royalty agreement (d) | |
| 3,259 | | |
| 3,936 | |
| |
| | | |
| | |
Total | |
| 118,467 | | |
| 149,684 | |
Current portion | |
| 42,332 | | |
| 37,803 | |
Long-term portion | |
$ | 76,135 | | |
$ | 111,882 | |
(a) French
government agencies provide financing to French companies for research and development. At December 31, 2014 and June 30, 2015,
the Company had outstanding loans of $3.7 million and $1.7 million, respectively for various programs. These loans do not bear
interest and are repayable only in the event the research project is technically or commercially successful. Potential repayment
is scheduled to occur from 2015 through 2019. In June 2015, the Company reimbursed $0.5 million in relation to a loan associated
with a specific research project conducted from 2003 to 2005. In addition, the Company recognized a waiver for repayment of the
remaining $1.1 million on the basis of limited commercial and technical success. The waiver is accounted for as a reduction to
R&D expenses.
FLAMEL TECHNOLOGIES
S.A.
Notes to Condensed
Consolidated Financial Statements
(Unaudited)
(b) The Acquisition
liability relates to the acquisition by the Company on March 13, 2012, through its wholly owned subsidiary Flamel US Holdings,
Inc., or Flamel US, of all of the membership interests of Éclat Pharmaceuticals, LLC. In exchange for all of the issued
and outstanding membership interests of Éclat Pharmaceuticals, Flamel US provided consideration consisting of:
| · | a $12 million senior, secured six-year note guaranteed by the Company and its subsidiaries and
secured by the equity interests and assets of Éclat. The note was repaid in full on March 24, 2014 generating a loss of
$3 million and accounted for in interest expense; |
| · | two warrants to purchase a total of 3,300,000 American Depositary Shares, each representing one
ordinary share of Flamel (“ADSs”); and |
| · | a commitment to make earnout payments of 20% of any gross profit generated by certain Éclat
Pharmaceuticals products. The Purchase Agreement also contains certain representations and warranties, covenants, indemnification
and other customary provisions. |
The fair
value of the warrants was determined by using a Black-Scholes option pricing model with the following assumptions:
| |
December
31, 2014 | | |
June
30, 2015 | |
Share
price | |
$ | 17.13 | | |
$ | 21.19 | |
Risk-free interest
rate | |
| 1.17 | % | |
| 0.92 | % |
Dividend
yield | |
| - | | |
| - | |
Expected
volatility | |
| 56.5 | % | |
| 62.90 | % |
Expected
term | |
| 3.3
years | | |
| 2.8
years | |
Pursuant
to guidance of ASC 815-40-15-7(i), the Company determined that the Warrants issued in March 2012 as consideration for the acquisition
of Éclat could not be considered as being indexed to the Company’s own stock, on the basis that the exercise price
for the warrants is determined in U.S. dollars, although the functional currency of the Company is the Euro. The Company determined
that these warrants should be accounted as a debt instrument.
As of June
30, 2015, the deferred consideration fair value was estimated by using a discounted cash flow model based on probability adjusted
annual gross profit of each of the Éclat Pharmaceuticals products. This fair value measurement is based on significant inputs
not observable in the market and thus represents a level 3 measurement as defined in ASC 820. The discount rate is 20%.
(c) On February
4, 2013 the Company concluded a $15 million debt financing transaction (Facility Agreement) with Deerfield Management a current
shareholder. The consideration received was as follows:
| · | $12.4 million for a facility agreement of a nominal value of $15 million, including a premium on
reimbursement of $2.6 million. The indebtedness was repaid on March 24, 2014 in its entirety, the accelerated reimbursement of
this note resulted in interest expenses of $2.5 million; |
| · | $2.6 million for a Royalty Agreement whereby, the Company’s wholly owned subsidiary Éclat
subject to required regulatory approvals and launch of product, is to pay a 1.75% Royalty of the net sales of certain products
sold by Éclat and any of its affiliates until December 31, 2024. |
FLAMEL TECHNOLOGIES
S.A.
Notes to Condensed
Consolidated Financial Statements
(Unaudited)
The fair
value of the Royalty was estimated using a probability-weighted discounted cash flow model based on probability adjusted projected
annual net sales of each of the products which may be approved and sold by Éclat Pharmaceuticals. This fair value measurement
is based on significant inputs not observable in the market and thus represents a level 3 measurement as defined in ASC 820. The
discount rate used is 20%.
(d) On December
3, 2013 the Company concluded with Broadfin Healthcare Master Fund, a current shareholder, a $15 million debt financing transaction
(Facility Agreement) divided in 3 tranches of $5 million each, Under the terms of the Facility, upon closing Broadfin made an initial
loan of $5.0 million. Consideration received was as follows:
| · | $2.8 million for a Facility agreement of a nominal value of $5.0 million. Loans under the Facility
were scheduled to mature upon the earlier to occur of (i) January 31, 2017 and (ii) the repayment in full of all outstanding amounts
under the Deerfield Facility, but in no event prior to November 15, 2015. The indebtedness was repaid on March 24, 2014 in its
entirety, the accelerated reimbursement of this note resulted in interest expenses of $ 2.2 million; |
| · | $2.2 million for a Royalty agreement whereby, the Company’s wholly owned subsidiary Éclat
subject to required regulatory approvals and launch of product, is to pay a 0.834% Royalty of the net sales of certain products
sold by Éclat and any of its affiliates until December 31, 2024. |
The fair
value of the Royalty was estimated using a probability-weighted discounted cash flow model based on probability adjusted projected
annual net sales of each of the products which may be approved and sold by Éclat Pharmaceuticals. This fair value measurement
is based on significant inputs not observable in the market and thus represents a level 3 measurement as defined in ASC 820. The
discount rate used is 20%.
Total contingent
and future payments on long-term debt for the next five years ending June 30 (assuming the various assumptions of the probability
adjusted annual gross profit and revenues of each of the Éclat Pharmaceuticals products and, as it relates to government
research loans, the underlying projects are commercially or technically successful for governmental research loans) are as follows:
(In thousands of U.S. dollars) | |
June 30, 2015 | |
| |
| |
| |
| |
2015 | |
| 19,846 | |
2016 | |
| 19,513 | |
2017 | |
| 21,814 | |
2018 | |
| 21,893 | |
2019 | |
| 16,691 | |
2020 | |
| 12,352 | |
| |
| | |
| |
| 112,109 | |
FLAMEL TECHNOLOGIES
S.A.
Notes to Condensed
Consolidated Financial Statements
(Unaudited)
11.
RELATED PARTY TRANSACTIONS
In March 2012, we
acquired, through our wholly owned subsidiary Flamel US Holdings, all of the membership interests of Éclat from Éclat
Holdings, an affiliate of Flamel’s largest shareholder Deerfield Capital L.P. The consideration consisted of a $12 million
senior, secured six-year note that is guaranteed by us and our subsidiaries and secured by the equity interests and assets of Éclat,
two warrants to purchase a total of 3,300,000 ADSs of Flamel and commitments to make earnout payments of 20% of any gross profit
generated by certain Éclat products and 100% of the gross profit generated by our former product Hycet®,
up to a maximum of $1 million, which we sold in 2013. The $12 million senior note was repaid in full in March 2014 using the net
proceeds from our public sale of ADSs and the Hycet® asset was disposed of in November 2013. Upon closing of the
acquisition, Mr. Anderson, the Chief Executive Officer of Éclat, was appointed Chief Executive Officer of Flamel. Mr. Anderson
retains a minority interest in Éclat Holdings, (now renamed Breaking Stick Holdings, LLC), and does not have the ability
to control this entity by virtue of his minority interest. The senior secured note was repaid in full in March 2014.
On February 4, 2013,
we entered into a Facility Agreement (the “Deerfield Facility”), through Flamel US with Deerfield Private Design Fund
II, L.P. and Deerfield Private Design International II, L.P. (together, the “Deerfield Entities”) providing for debt
financing of $15 million by the Deerfield Entities (the “Loan”). The loan was repaid in full in March 2014 using the
net proceeds from our public sale of ADSs.
In conjunction with
our entry into the Deerfield Facility, Éclat entered into a Royalty Agreement with Horizon Santé FLML, Sarl and Deerfield
Private Design Fund II, L.P., both affiliates of the Deerfield Entities (together, “Deerfield PDF/Horizon”). The Royalty
Agreement provides for Éclat to pay Deerfield PDF/Horizon 1.75% of the net sales price of the products sold by us and any
of our affiliates until December 31, 2024, with royalty payments accruing daily and paid in arrears for each calendar quarter during
the term of the Royalty Agreement.
We have also entered
into a Security Agreement dated February 4, 2013 with Deerfield PDF/Horizon, whereby Deerfield PDF/Horizon was granted a security
interest in the intellectual property and regulatory rights related to the products to secure the obligations of Éclat and
Flamel US, including the full and prompt payment of royalties to Deerfield PDF/Horizon under the Royalty Agreement.
On December 3, 2013,
we and certain of our U.S. subsidiaries entered into a Facility Agreement (the “Broadfin Facility”) with Broadfin Healthcare
Master Fund, Ltd. (“Broadfin”) providing for loans by Broadfin in an aggregate amount not to exceed $15.0 million.
The loans under the Broadfin Facility and the obligations under the Royalty Agreement were secured by a first priority security
interest in intellectual property associated with our Medusa technology and a junior lien on substantially all of the assets of
the borrowers, which were previously pledged in connection with the Deerfield Facility, the Royalty Agreement and the notes issued
in connection with the Éclat acquisition.
Under the terms of the
Broadfin Facility, upon closing Broadfin made an initial loan of $5.0 million and we had the ability to request, at any time prior
to August 15, 2014, up to two additional loans in the amount of $5.0 million each, with funding subject to certain specified conditions.
We had the ability to prepay the outstanding loans under the Broadfin Facility at any time, without prepayment penalty and the
full $5.0 million outstanding was subsequently repaid using a portion of the net proceeds from our public sale of ADSs in March
2014.
In connection with entering
into the Broadfin Facility, we also entered into a Royalty Agreement with Broadfin, dated as of December 3, 2013 (the “Broadfin
Royalty Agreement”). Pursuant to the Broadfin Royalty Agreement, we are required to pay a royalty of 0.834% on the net sales
of certain products sold by Éclat Pharmaceuticals, LLC and any of its affiliates until December 31, 2024.
FLAMEL TECHNOLOGIES
S.A.
Notes to Condensed
Consolidated Financial Statements
(Unaudited)
12. FAIR
VALUE OF FINANCIAL INSTRUMENTS
At December
31, 2014 and June 30, 2015, the carrying values of financial instruments such as cash and cash equivalents, trade receivables and
payables, other receivables and accrued liabilities and the current portion of long-term debt approximated their market values,
based on the short-term maturities of these instruments.
The company
calculates fair values for its marketable securities based on quoted market prices for identical assets and liabilities which represent
Level 1 of the ASC 820-10 fair value hierarchy.
At December
31, 2014 and June 30, 2015 the fair values of long-term debt and long-term receivables were comparable with their respective carrying
values.
The following
table presents information about the Company securities based on quoted market prices for identical assets and liabilities for
June 30, 2015 and indicates the fair value hierarchy of the valuation techniques utilized to determine such fair value.
| |
| | |
| | |
| | |
| | |
| | |
six months
ended June, 30 2015 | | |
| | |
six months
ended June,30 2014 | |
(in
thousands of US Dollars) | |
Net Carrying
Value as of December 31, 2014 | | |
Net Carrying
Value as of June 30, 2015 | | |
Fair Value
Measured and Recorded Using | | |
Operational
Gain (losses) recognized in earnings | | |
Financial Gain
(losses) recognized in earnings | | |
Total | | |
Operational
Gain (losses) recognized in earnings | | |
Financial Gain
(losses) recognized in earnings | | |
Total | |
| |
| | |
| | |
Level 1 | | |
Level 2 | | |
Level 3 | | |
| | |
| | |
| | |
| | |
| | |
| |
Assets | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Cash and cash equivalent | |
| 39,760 | | |
| 55,236 | | |
| 55,236 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | |
Marketable
securities | |
| 53,074 | | |
| 60,884 | | |
| 60,884 | | |
| - | | |
| - | | |
| - | | |
| 659 | | |
| 659 | | |
| - | | |
| - | | |
| - | |
Total | |
| | | |
| | | |
| | | |
| - | | |
| - | | |
| - | | |
| 659 | | |
| 659 | | |
| | | |
| | | |
| | |
| |
| | |
| | |
| | |
| | |
| | |
six months ended June, 30 2015 | | |
six months ended June,30 2014 | |
(in thousands of US Dollars) | |
Net Carrying
Value as of December 31, 2014 | | |
Net Carrying
Value as of June 30, 2015 | | |
Fair Value Measured and Recorded Using | | |
Operational Gain
(losses) recognized in earnings "Fair Value remeasurement of Acquisition liabilities" | | |
Financial Gain (losses)
recognized in earnings "Interest expense on debt related to the royalty agreement " | | |
Total | | |
Operational Gain (losses)
recognized in earnings "Fair Value remeasurement of Acquisition liabilities" | | |
Financial Gain (losses)
recognized in earnings "Interest expense on debt related to the royalty
agreement " | | |
Total | |
| |
| | |
| | |
Level 1 | | |
Level 2 | | |
Level 3 | | |
| | |
| | |
| | |
| | |
| | |
| |
Liabilities | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Acquisition liability contingent consideration
(a) | |
| 70,112 | | |
| 89,077 | | |
| - | | |
| - | | |
| 89,077 | | |
| (25,083 | ) | |
| - | | |
| (25,083 | ) | |
| (8,862 | ) | |
| | | |
| (8,862 | ) |
Acquisition liability note (b). | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| | | |
| | | |
| - | | |
| (3,013 | ) | |
| | | |
| (3,013 | ) |
Acquisition liability warrant consideration (c) | |
| 34,542 | | |
| 46,713 | | |
| - | | |
| - | | |
| 46,713 | | |
| (12,171 | ) | |
| - | | |
| (12,171 | ) | |
| (18,371 | ) | |
| - | | |
| (18,371 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Deerfield Royalty Agreement (d) | |
| 6,837 | | |
| 8,256 | | |
| | | |
| | | |
| 8,256 | | |
| | | |
| (2,021 | ) | |
| (2,021 | ) | |
| | | |
| (836 | ) | |
| (836 | ) |
Broadfin
Royalty Agreement (d) | |
| 3,259 | | |
| 3,936 | | |
| | | |
| | | |
| 3,936 | | |
| | | |
| (964 | ) | |
| (964 | ) | |
| - | | |
| (399 | ) | |
| (399 | ) |
Total | |
| 114,750 | | |
| 147,982 | | |
| | | |
| | | |
| 147,982 | | |
| (37,254 | ) | |
| (2,985 | ) | |
| (40,239 | ) | |
| (30,246 | ) | |
| (1,235 | ) | |
| (31,481 | ) |
The fair
values of the financial instruments in connection with the acquisition of Éclat (see note 10 Long-Term Debt) are
estimated as follows:
(a) Acquisition
liability contingent consideration: the fair value is estimated using a discounted cash flow model based on probability adjusted
projected annual gross profit of each of the products which formed the project portfolio at the time of acquisition of Éclat
Pharmaceuticals (Note 10 Long Term Debt).
The fair
value of the contingent consideration will change over time in accordance with the changes in market conditions and business plan
projections as it relates to market size, market share, product pricing, competitive landscape, and gross profit margins expected
for each of the products.
(b) Acquisition
liability Note: the Company uses a probability-weighted discounted cash flow model (see note 10 Long Term Debt). The note
was repaid on March 24, 2014.
FLAMEL TECHNOLOGIES
S.A.
Notes to Condensed
Consolidated Financial Statements
(Unaudited)
(c) Acquisition
liability warrant consideration: the Company uses a Black-Scholes option pricing model. The fair value of the warrant consideration
will change over time depending on the volatility and share price at balance sheet date (see note 10 Long Term Debt).
(d) Broadfin
and Deerfield Royalty Agreement: the fair value is estimated using a discounted cash flow model based on probability adjusted projected
annual net sales of each of the products which may be approved and sold by Éclat Pharmaceuticals (Note 10 Long Term
Debt). The discount rate used is 20%.
The following tables provide
a reconciliation of fair value for which the Company used Level 3 inputs:
(in thousands of US Dollars) | |
Acquisition | |
| |
Liabilities | |
Liability recorded upon acquisition | |
$ | (50,927 | ) |
Operational gain (loss) recognized in earnings for fiscal year 2012 & 2013 | |
| (9,142 | ) |
Payment deferred consideration (Hycet) & interest on acquisition liability note. | |
| 1,176 | |
Net carrying value at January 1, 2014. | |
| (58,893 | ) |
Operational gain (loss) recognized in earnings for fiscal year 2014... | |
| (60,503 | ) |
Reimbursment of acquisition liability note. | |
| 12,000 | |
Payment of interest on acquisition liability note.. | |
| 1,389 | |
Payment of deferred consideration. | |
| 1,354 | |
| |
| | |
Net carrying value at January 1, 2015. | |
| (104,653 | ) |
Fair value remeasurement recognized in earnings for six months to June 30, 2015 | |
| (37,254 | ) |
Payment of deferred consideration. | |
| 6,117 | |
Net carrying value at June 30, 2015 | |
$ | (135,791 | ) |
(in thousands of US Dollars) | |
Deerfield Royalty | | |
Broadfin Royalty | |
| |
Agreement | | |
Agreement | |
Liability recorded upon execution of Agreeement | |
$ | (2,600 | ) | |
$ | (2,187 | ) |
Interest expense recognized in earnings for 2013 | |
| (1,990 | ) | |
| | |
Interest expense recognized in earnings for 2014 | |
| (2,386 | ) | |
| (1,139 | ) |
Payment of Royalty 2014 | |
| 140 | | |
| 67 | |
Net carrying value at Jan 1, 2015 | |
| (6,837 | ) | |
| (3,259 | ) |
Interest expense recognized in earnings for 6 months to June 30, 2015 | |
| (2,021 | ) | |
| (964 | ) |
Payment of Royalty | |
| 601 | | |
| 287 | |
Net carrying value at June 30, 2015 | |
$ | (8,257 | ) | |
$ | (3,936 | ) |
The acquisition
liabilities, consisting of the warrants and deferred consideration, and Royalty agreement all of which are classified as long-term
debt, are measured at fair value and the income or expense may change significantly as assumptions regarding the valuations and
probability of successful development and approval of products in development vary.
13. Subsequent
events
The
Company determines the fair value of contingent consideration and royalty agreements, classified as long term debt, by
reference to a probability-weighted discounted cash flow model. The model changes over time as a result of changes in market
conditions and including market size, market share, product pricing, competitive landscape, and gross profit margins expected
for each of the products. Subsequent to June 30, 2015 the Company received acceptance from the FDA of its third NDA filing
and observed changes in market conditions related to price increases implemented on competitor products and related to market
share. Such events occurring subsequent to the balance sheet date have modified business plan projections and
corresponding cash flows, which has resulted in a corresponding increase in the fair value of contingent consideration and
royalty agreements of $56.0 million to reach $146.6 million as of September 30, 2015. The Company is evaluating the financial
impact of events occurring subsequent to September 30, 2015 on the fair value of contingent consideration and royalty
agreements.
Item
2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Forward-Looking
Statements
This report on Form
6-K contains forward-looking statements. We may make additional written or oral forward-looking statements from time to time in
filings with the Securities and Exchange Commission or otherwise. The words “will,” “may”, ”believe,”
“expect,” “anticipate,” “estimate,” “project,” and the negative of these and similar
expressions identify forward-looking statements, which speak only as of the date the statement is made. Such forward-looking statements
are within the meaning of that term in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Although we believe that our forward-looking statements are based on reasonable assumptions within the bounds of our
knowledge of our business and operations, our business is subject to significant risks and there can be no assurance that actual
results of our research, development and commercialization activities and our results of operations will not differ materially from
our expectations.
Forward-looking statements
are subject to inherent risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results
could differ materially from those set forth in, contemplated by or underlying the forward-looking statements. We undertake no
obligation to update these forward-looking statements as a result of new information, future events or otherwise. You should not
place undue reliance on these forward looking statements. Factors that could cause actual results to differ from expectations include,
among others, those listed in Part II, Item 1A, Risk Factors of this Form 6-K and set forth in more detail in “Risk Factors”
in our Form 20-F for the fiscal year ended December 31, 2014.
RESULTS OF OPERATIONS – Three months ended June 30,
2015 compared to three months ended June 30, 2014
For the three months
ended June 30, 2015, revenues were $49.8 million compared to $4.3 million for the same quarter of 2014. This increase was driven
from higher sales of Bloxiverz of $43.3 million resulting from market share gains and higher net selling prices. The launch of
Vazculep also contributed to the sales increase and generated $3.6 million of higher sales when compared to the same period last
year.
Costs of goods and
services sold were $2.8 million in the three-month period ended June 30, 2015 compared to $0.5 million for the three-month
period ended June 30, 2014. This increase is due to the increase in product sales.
Research and development
expenditures increased to $7.2 million in the three months ended June 30, 2015 compared to $3.6 million in the three months ended
June 30, 2014. This increase results from a $2.3 million filing fee for the third Éclat product and the Company’s
continued investment in its pipeline products.
Selling, general and
administrative expenses increased to $5.9 million in the three months ended June 30, 2015 compared to $4.1 million in the
three months ended June 30, 2014. This increase results from higher non-cash stock compensation expenses and recruitment costs
associated with the Company’s efforts to reinforce its management team.
Fair value remeasurement
of acquisition liabilities increased from $12.6 million in the three-month period ended June 30, 2014 to $32.0 million in
the three-month period ended June 30, 2015. This increase reflects management’s assessment that the earn-out to be paid on
future product sales is higher than in the past.
Amortization of intangible
assets associated with the development of Bloxiverz and Vazculep amounts to $3.1 million for the three-month period ended June
30, 2015 compared with $2.9 million in the prior period. Amortization of R&D assets associated with Vazculep started on January
1, 2015 generating an increase in amortization expense year over year.
Foreign exchange loss
amounted to $3.6 million for the three-month period ended June 30, 2015 compared with a $0.3 million foreign exchange loss in the
prior period. The fluctuation results from the weakening of the USD over the second quarter of 2015 and the corresponding impact
on the valuation of assets denominated in USD that are recorded in the accounts of the parent company for which the functional
currency is the Euro.
Income tax expense
amounted to $10.2 million for the three-month period ended June 30, 2015 compared to $0.1 million in the prior period. Income tax
expense is generated essentially from our operations in the US. Higher pre-tax income in the U.S. drove the higher tax expense.
Our R&D expenses are essentially incurred in Europe prohibiting the offset of such expenses to income generated in the US.
Net loss for the three-month
period ended June 30, 2015 was $17.4 million, compared to a net loss of $21.1 million in the three-month period ended June 30,
2014. Net loss per share (basic) for the three-month period ended June 30, 2015 was ($0.43), compared to a net loss per share in
the year-ago period of ($0.53).
RESULTS OF OPERATIONS – Six months ended June 30, 2015
compared to six months ended June 30, 2014
For the six months ended
June 30, 2015, revenues were $82.5 million compared to $8.9 million reported for the same period in 2014. This increase was driven
from higher sales of Bloxiverz of $68.5 million resulting from market share gains and higher net selling prices. The launch of
Vazculep also contributed to the sales increase and generated $7.2 million of higher sales when compared to the same period last
year
Costs of goods and
services sold were $6.4 million in the six-month period ended June 30, 2015 compared to $1.3 million for the six-month
period ending June 30, 2014. This increase is due to the increase in product sales.
Research and development
expenditures increased to $13.2 million in the six months ended June 30, 2015 compared to $7.5 million in the six months ended
June 30, 2014. This increase results from a $2.3 million filing fee for the third Éclat product and the Company’s
continued investment in its pipeline products.
Selling, general and
administrative expenses increased to $10.3 million in the six months ended June 30, 2015, compared to $7.6 million in the six months
ended June 30, 2014. This increase results from higher non-cash stock compensation expenses and recruitment costs associated
with the Company’s efforts to reinforce its management team.
Fair value remeasurement
of acquisition liabilities increased to $37.2 million in the six months ended June 30, 2015 from $27.2 million in the six months
ended June 30, 2014. This increase reflects management’s assessment that the earn-out to be paid on future product sales
has increased from one period to another.
Amortization of intangible
assets associated with the development of Bloxiverz and Vazculep amounts to $6.3 million for the six-month period ended June 30,
2015 compared with $5.9 million in the prior period. Amortization of R&D assets associated with Vazculep started on January
1, 2015 generating an increase in the non-cash tax charge year over year.
Acquisition note expense
amounted to $3.0 million in the six-month period ended June 30, 2014 and represents the loss incurred following early repayment
of debt for the acquisition of Éclat Pharmaceuticals in March 2014.
Interest expense was
$0.5 million in the six-month period ended June 30, 2015 compared to $5.6 million in the same prior year period as a result of
lower debt levels due to the early repayment of debt in March 2014.
Foreign exchange gain
increased to $7.9 million for the six-month period ended June 30, 2015 from $0.5 million in the prior period as a result of the
strengthening of the USD which increases the value of assets denominated in USD that are recorded in the accounts of the parent
company whose functional currency is the Euro.
Income
tax expense amounted to $20.7 million for the six-month period ended June 30, 2015 compared to $2.7 million in the prior period.
Income tax expense is generated essentially from our operations in the US. Higher pre-tax income in the U.S. drove the higher tax
expense. Our R&D expenses are essentially incurred in Europe prohibiting the offset of such expenses to income generated in
the US. Flamel has utilized the majority of US net operating losses carry-forwards and
will remit income tax payments to the IRS on a quarterly basis.
Net loss for the six-month
period ended June 30, 2015 was $5.8 million, compared to a net loss of ($47.7) million in the six-month period ended June 30,
2014. Net loss per share (basic) for the six-month period ended June 30, 2015 was ($0.14), compared to a net loss per share in
the year-ago period of ($1.41).
LIQUIDITY AND CAPITAL
RESOURCES
As of June 30, 2015,
the Company had $116.1 million in cash, cash equivalents and marketable securities, compared to $92.8 million on December 31,
2014. This increase was principally driven from operating cash flow of $39.3 million partially offset by cash used for financing
activities of $10.9 million. The Company believes it has sufficient funds to finance operations for the next twelve months which
will include continued investment in pharmaceutical development of its pipeline products.
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
While we may be engaged
in various claims and legal proceedings in the ordinary course of business, we are not involved (whether as a defendant or otherwise)
in and we have no knowledge of any threat of, any litigation, arbitration or administrative or other proceeding which management
believes will have a material adverse effect on our consolidated financial position or results of operations.
Item 1A. Risk Factors
Item 3, “Key
Information - Risk Factors,” of our Annual Report on Form 20-F for the year ended December 31, 2014 describes some of the
risks and uncertainties associated with our business. The risk factors set forth below highlight some of these risk disclosures.
Other factors may also exist that we cannot anticipate or that we currently do not consider to be significant based on information
that is currently available. In addition to the other information in our SEC filings, you should consider carefully the following
risk factors. The occurrence of any one or more of the risks or uncertainties described below or in our Form 20-F could have a
material adverse effect on our business, financial condition and results of operations, cash flows and future results:
| · | we depend on a small number of products
and customers for the majority of our revenues and the loss of any one of these products or customers could reduce our revenues
significantly. |
| · | our Bloxiverz® and Vazculep™
products are not patent protected and could face substantial competition resulting in a loss of market share or forcing us to reduce
the prices we charge for those products, which would have a material adverse effect on our revenues and results of operation. |
| · | we could fail to successfully complete
the research and development for the two pipeline products we are evaluating for potential application to the FDA pursuant to our
UMD strategy, or our competitors could complete the development of such products and apply for FDA approval of such products before
us, which would have a material adverse effect on our future business opportunities. |
| · | we may depend on partnership arrangements
or strategic alliances for the commercialization of some of our products, and the failure of any third party to fulfill its duties
under such an arrangement or alliance could have a material adverse effect on our financial condition and results of operation. |
| · | our products may not gain market acceptance,
and lack of such market acceptance would limit our ability to generate revenue which would have a material adverse effect on our
business. |
| · | our products may not reach the commercial
market for a number of reasons, which would adversely affect our future revenues. |
| · | we must invest substantial sums in research
and development (“R&D”) in order to remain competitive, and we may not fully recover these investments. |
| · | the development of several of our drug
delivery platforms and products depends on the services of a single provider and any interruption of such provider’s operations
could significantly delay or have a material adverse effect on our product pipeline. |
| · | we depend upon a limited number of suppliers
to manufacture our products and to deliver certain raw materials used in our products and the failure of any such supplier to timely
deliver sufficient quantities of products or raw materials could have a material adverse effect on our business. |
| · | if our competitors develop and market
technologies or products that are more effective or safer than ours, or obtain regulatory approval and market such technologies
or products before we do, our commercial opportunity will be diminished or eliminated. |
| · | if we cannot adequately protect our drug
delivery platforms and proprietary information, we may be unable to sustain a competitive advantage. |
| · | we depend on key personnel to execute
our business plan and the loss of any one or more of these key personnel may limit our ability to effectively pursue our business
plan. |
In addition to the foregoing risks, the Company’s
growth and expansion could adversely affect its internal control over financial reporting, which could harm its business and financial
results.
Our management is responsible for establishing and
maintaining adequate internal control over financial reporting in order to provide reasonable assurance regarding the reliability
of such financial reporting for external purposes in accordance with GAAP. Any system of internal control over financial
reporting has inherent limitations and therefore cannot be expected to, and is not intended to, provide absolute assurance that
a misstatement of the Company’s financial statements will be prevented or detected.
Over the past several years, the Company has experienced
growth in the size and geographic presence of its business activities and operations. This growth has placed, and our anticipated
future growth will continue to place, significant demands on our management and administrative resources, including our system
of internal control over financial reporting. As a result, it will be necessary for us to continue to implement and improve
our operating, administrative, financial and accounting systems and controls, including our system of internal control over financial
reporting. Any failure to maintain an effective system of internal control over financial reporting could limit the Company’s
ability to report its financial results accurately and on a timely basis, or to detect and prevent fraud.
INCORPORATION BY REFERENCE
This report
on Form 6-K including any exhibits included herewith are incorporated by reference into Registration Statement No. 333-183961 on
Form F-3 originally filed on September 18, 2012 and Registration Statement No. 333-193898 on Form F-3 originally filed on February
12, 2014, and shall be deemed a part of such registration statements from the date on which this report on Form 6-K is filed to
the extent not superseded by documents or reports subsequently filed or furnished by Flamel Technologies S.A. under the Securities
Act of 1933 or the Securities Exchange Act of 1934.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
Flamel Technologies, S.A. |
|
|
Dated: December
31, 2015 |
/s/ Michael S. Anderson |
|
Michael S. Anderson |
|
Chief Executive Officer |
v3.3.1.900
X |
- DefinitionIf the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionEnd date of current fiscal year in the format --MM-DD.
+ References
+ Details
Name: |
dei_CurrentFiscalYearEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:gMonthDayItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThis is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
+ Details
Name: |
dei_DocumentFiscalPeriodFocus |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fiscalPeriodItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThis is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
+ Details
Name: |
dei_DocumentFiscalYearFocus |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:gYearItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation 12B -Number 240 -Section 12b -Subsection 1
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
+ Details
Name: |
dei_EntityCommonStockSharesOutstanding |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionIndicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
+ Details
Name: |
dei_EntityFilerCategory |
Namespace Prefix: |
dei_ |
Data Type: |
dei:filerCategoryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation 12B -Number 240 -Section 12b -Subsection 1
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands |
3 Months Ended |
6 Months Ended |
Jun. 30, 2015 |
Jun. 30, 2014 |
Jun. 30, 2015 |
Jun. 30, 2014 |
Revenue: |
|
|
|
|
License and research revenue |
$ 0
|
$ 1,819
|
$ 0
|
$ 2,417
|
Product sales and services |
49,795
|
2,499
|
82,521
|
6,479
|
Total revenue |
49,795
|
4,318
|
82,521
|
8,896
|
Costs and expenses: |
|
|
|
|
Cost of goods and services sold |
(2,756)
|
(507)
|
(6,386)
|
(1,280)
|
Research and development |
(7,204)
|
(3,600)
|
(13,226)
|
(7,544)
|
Selling, general and administrative |
(5,873)
|
(4,065)
|
(10,336)
|
(7,581)
|
Fair value remeasurement of acquisition liabilities, with related parties |
(32,000)
|
(12,607)
|
(37,254)
|
(27,233)
|
Amortisation of intangible R&D assets |
(3,139)
|
(2,938)
|
(6,282)
|
(5,875)
|
Acquisition note expenses with related parties |
|
|
0
|
(3,013)
|
Total |
(50,972)
|
(23,717)
|
(73,484)
|
(52,526)
|
Operating profit (loss) |
(1,177)
|
(19,399)
|
9,037
|
(43,630)
|
Net interest income (expense) |
310
|
123
|
1,456
|
220
|
Interest expense |
|
|
(482)
|
(5,552)
|
Interest expense on debt related to the royalty agreement with related parties |
(2,726)
|
(1,079)
|
(2,985)
|
(1,235)
|
Foreign exchange gain (loss) |
(3,565)
|
292
|
7,936
|
471
|
Income (loss) before income taxes |
(7,158)
|
(20,063)
|
14,962
|
(49,726)
|
Income tax benefit (expense) |
(10,242)
|
(137)
|
(20,715)
|
2,665
|
Net income (loss) from continuing operations |
(17,400)
|
(20,200)
|
(5,753)
|
(47,061)
|
Net income (loss) from discontinued operations |
0
|
(873)
|
0
|
(650)
|
Net income (loss) |
$ (17,400)
|
$ (21,073)
|
$ (5,753)
|
$ (47,711)
|
Earnings (loss) per ordinary share (Basic and Diluted) |
|
|
|
|
Continuing operations |
$ (0.43)
|
$ (0.53)
|
$ (0.14)
|
$ (1.41)
|
Discontinued operations |
0
|
(0.02)
|
0
|
(0.02)
|
Net income (loss) |
$ (0.43)
|
$ (0.55)
|
$ (0.14)
|
$ (1.43)
|
Weighted average number of shares outstanding (in thousands) : |
|
|
|
|
Basic (in shares) |
40,353
|
38,438
|
40,281
|
33,403
|
Diluted (in shares) |
40,353
|
38,438
|
40,281
|
33,403
|
X |
- DefinitionRepresents the fair value measurement of acquisition liabilities
+ References
+ Details
Name: |
flml_FairValueMeasurementOfAcquisitionLiabilities |
Namespace Prefix: |
flml_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionRevenue earned during the period relating to licensing fees and research revenue.
+ References
+ Details
Name: |
flml_LicenseAndResearchRevenue |
Namespace Prefix: |
flml_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAggregate revenue during the period from the sale of goods in the normal course of business and also from providing service for the goods.
+ References
+ Details
Name: |
flml_SalesRevenueGoodsAndServicesNet |
Namespace Prefix: |
flml_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275
+ Details
Name: |
us-gaap_AmortizationOfIntangibleAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(a),(d)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_CostOfGoodsAndServicesSold |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionTotal costs of sales and operating expenses for the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_CostsAndExpenses |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_CostsAndExpensesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPer basic and diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation, when the per share amount is the same.
+ References
+ Details
Name: |
us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
+ Details
Name: |
us-gaap_EarningsPerShareBasicAndDiluted |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_EarningsPerShareBasicAndDilutedAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 20 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6450189&loc=d3e30700-110894
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 20 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6450189&loc=d3e30690-110894
+ Details
Name: |
us-gaap_ForeignCurrencyTransactionGainLossBeforeTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThis element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items, and noncontrolling interest.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 19 -URI http://asc.fasb.org/extlink&oid=51664549&loc=SL4569616-111683
+ Details
Name: |
us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.
+ References
+ Details
Name: |
us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.12) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 5C -Subparagraph (b)(2) -URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721675-107760
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.14) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=51716988&loc=d3e1012-107759
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 45 -Paragraph 3B -URI http://asc.fasb.org/extlink&oid=51716988&loc=SL51721525-107759
Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 45 -Paragraph 3A -URI http://asc.fasb.org/extlink&oid=51716988&loc=SL51721523-107759
Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=51716988&loc=d3e957-107759
Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=51717284&loc=d3e1361-107760
Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 13 -Article 7
Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 15 -Article 5
+ Details
Name: |
us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of the cost of borrowed funds accounted for as interest expense.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.9) -URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details
Name: |
us-gaap_InterestExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.8) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_InterestExpenseDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe net amount of operating interest income (expense).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.10) -URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details
Name: |
us-gaap_InterestIncomeExpenseNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=51831255
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.19) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.18) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.22) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=51831270
Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5
Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe net result for the period of deducting operating expenses from operating revenues.
+ References
+ Details
Name: |
us-gaap_OperatingIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756
+ Details
Name: |
us-gaap_ResearchAndDevelopmentExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_RevenuesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTotal revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_SalesRevenueNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 330 -SubTopic 10 -Section 30 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=51677171&loc=d3e3636-108311
+ Details
Name: |
us-gaap_SellingGeneralAndAdministrativeExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 16 -URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details
Name: |
us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Weighted-Average Number of Common Shares Outstanding -URI http://asc.fasb.org/extlink&oid=6528421
+ Details
Name: |
us-gaap_WeightedAverageNumberOfSharesOutstandingBasic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands |
3 Months Ended |
6 Months Ended |
Jun. 30, 2015 |
Jun. 30, 2014 |
Jun. 30, 2015 |
Jun. 30, 2014 |
Net Income (loss) |
$ (17,400)
|
$ (21,073)
|
$ (5,753)
|
$ (47,711)
|
Other comprehensive income (loss): |
|
|
|
|
Net foreign currency translation gain (loss) |
5,262
|
(1,257)
|
(11,387)
|
(2,025)
|
Unrealized gain (loss) on marketable Securities |
(356)
|
0
|
0
|
0
|
Other comprehensive income (loss), net of tax |
4,906
|
(1,257)
|
(11,387)
|
(2,025)
|
Comprehensive Income (loss) |
$ (12,494)
|
$ (22,330)
|
$ (17,140)
|
$ (49,736)
|
X |
- DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=51831270
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Comprehensive Income -URI http://asc.fasb.org/extlink&oid=51831223
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e557-108580
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=51831255
+ Details
Name: |
us-gaap_ComprehensiveIncomeNetOfTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=51831255
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.19) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.18) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.22) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=51831270
Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5
Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 30 -Section 45 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32211-110900
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 10A -Subparagraph (a-c) -URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 30 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 30 -Section 45 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32022-110900
Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 30 -Section 45 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32157-110900
+ Details
Name: |
us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount after tax of other comprehensive income (loss) attributable to parent entity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1A -Subparagraph (c)(3) -URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 19 -URI http://asc.fasb.org/extlink&oid=51664549&loc=SL4569616-111683
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=51664549&loc=SL4569643-111683
+ Details
Name: |
us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount before tax and reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 10A -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580
+ Details
Name: |
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
v3.3.1.900
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands |
Jun. 30, 2015 |
Dec. 31, 2014 |
Current assets: |
|
|
Cash and cash equivalents |
$ 55,236
|
$ 39,760
|
Marketable securities |
60,884
|
53,074
|
Accounts receivable (net of allowance of $127 and $118 at December 31, 2014, and June 30, 2015 respectively) |
3,498
|
1,679
|
Inventory |
5,751
|
6,729
|
Research and development tax credit receivable |
1,609
|
5,932
|
Prepaid expenses and other current assets |
5,189
|
4,418
|
Total current assets from continuing operations |
132,167
|
111,592
|
Total current assets from assets held for sale |
0
|
730
|
Goodwill, net |
18,491
|
18,491
|
Property and equipment, net |
1,978
|
1,776
|
Intangible assets |
22,107
|
28,389
|
Other assets: |
|
|
Income tax deferred charge |
11,685
|
13,102
|
Other long-term assets |
117
|
125
|
Total long term assets from continuing operations |
54,378
|
61,883
|
Total assets including "assets held for sale" |
186,545
|
174,205
|
Current liabilities: |
|
|
Current portion of long-term debt, incl to related parties |
37,803
|
42,332
|
Accounts payable |
11,403
|
8,024
|
Deferred revenue |
21
|
1,336
|
Accrued expenses |
3,096
|
5,667
|
Other current liabilities |
349
|
5,672
|
Income tax payable |
77
|
7,643
|
Total current liabilities from continuing operations |
52,749
|
70,674
|
Total current liabilities from liabilities held for sale |
0
|
168
|
Long-term debt, less current portion, incl. to related parties |
111,882
|
76,135
|
Deferred tax liabilities |
6,071
|
0
|
Other long-term liabilities |
2,206
|
2,333
|
Total long-term liabilities from continuing operations |
120,159
|
78,468
|
Shareholders' equity: |
|
|
Ordinary shares: 40,191,264 issued and outstanding at December 31, 2014 and 40,498,764 at June 30, 2015 (shares authorised 52,549,354) at nominal value of 0.122 euro |
6,229
|
6,188
|
Additional paid-in capital |
352,423
|
346,582
|
Accumulated deficit |
(326,205)
|
(320,452)
|
Accumulated other comprehensive income (loss) |
(18,810)
|
(7,423)
|
Total shareholders' equity |
13,637
|
24,895
|
Total liabilities and shareholders' equity including held for sale |
$ 186,545
|
$ 174,205
|
X |
- DefinitionThe current portion of tax credit receivable on research and development as on the balance sheet date.
+ References
+ Details
Name: |
flml_ResearchAndDevelopmentTaxCreditReceivableCurrent |
Namespace Prefix: |
flml_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_AccountsPayableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.3-4) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 3 -Subparagraph a(1) -Article 5
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 4 -Article 5
+ Details
Name: |
us-gaap_AccountsReceivableNetCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_AccruedLiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAccumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669686-108580
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3
+ Details
Name: |
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionValue received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.30(a)(1)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5
+ Details
Name: |
us-gaap_AdditionalPaidInCapitalCommonStock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.18) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 12 -Article 7
+ Details
Name: |
us-gaap_Assets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.9) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
+ Details
Name: |
us-gaap_AssetsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_AssetsCurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.10-17) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 18 -Article 5
+ Details
Name: |
us-gaap_AssetsNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 45 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=51716988&loc=d3e1107-107759
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=51716988&loc=SL51721533-107759
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=51719941&loc=d3e2941-110230
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 5B -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721673-107760
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=51824106&loc=d3e2473-110228
+ Details
Name: |
us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash Equivalents -URI http://asc.fasb.org/extlink&oid=6507016
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_CashAndCashEquivalentsAtCarryingValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5
+ Details
Name: |
us-gaap_CommonStockValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A
+ Details
Name: |
us-gaap_DeferredRevenueCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, netted by jurisdiction and classified as current.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31917-109318
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31931-109318
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319
+ Details
Name: |
us-gaap_DeferredTaxAssetsLiabilitiesNetCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount, after deferred tax asset, of deferred tax liability attributable to taxable differences, netted by jurisdiction and classified as noncurrent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31931-109318
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 45 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31958-109318
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31917-109318
+ Details
Name: |
us-gaap_DeferredTaxLiabilitiesNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266
+ Details
Name: |
us-gaap_Goodwill |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph ((a)(1),(b)) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275
+ Details
Name: |
us-gaap_IntangibleAssetsNetExcludingGoodwill |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.6(a)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 330 -SubTopic 10 -Section 35 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=51655945&loc=d3e3927-108312
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
+ Details
Name: |
us-gaap_InventoryNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.32) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 25 -Article 7
+ Details
Name: |
us-gaap_LiabilitiesAndStockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.21) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_LiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_LiabilitiesCurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of obligation due after one year or beyond the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22-26) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 22, 23, 24, 25, 26, 27 -Article 5
+ Details
Name: |
us-gaap_LiabilitiesNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 5B -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721673-107760
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 45 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=51716988&loc=d3e1107-107759
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=51824106&loc=d3e2473-110228
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=51716988&loc=SL51721533-107759
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=51719941&loc=d3e2941-110230
+ Details
Name: |
us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of long-term debt, after unamortized discount or premium, scheduled to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_LongTermDebtCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_LongTermDebtNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=49167202&loc=d3e26626-111562
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.2) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_MarketableSecuritiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_OtherAssetsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6904-107765
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765
+ Details
Name: |
us-gaap_OtherLiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.24) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_OtherLiabilitiesNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionOther long-term investments not otherwise specified in the taxonomy, not including investments in marketable securities.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.1(f)) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.12) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_OtherLongTermInvestments |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 8 -Article 5
+ Details
Name: |
us-gaap_PrepaidExpenseAndOtherAssetsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.13) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 13 -Subparagraph a -Article 5
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 8 -Article 7
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionThe cumulative amount of the reporting entity's undistributed earnings or deficit.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.31(a)(3)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3
+ Details
Name: |
us-gaap_RetainedEarningsAccumulatedDeficit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E
+ Details
Name: |
us-gaap_StockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_StockholdersEquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCarrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_TaxesPayableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.3.1.900
Condensed Consolidated Balance Sheets [Parenthetical] $ in Thousands |
Jun. 30, 2015
USD ($)
shares
|
Jun. 30, 2015
€ / shares
|
Dec. 31, 2014
USD ($)
shares
|
Dec. 31, 2014
€ / shares
|
Allowance for accounts receivable (in dollars) | $ |
$ 118
|
|
$ 127
|
|
Common stock, par value (in euro per share) | € / shares |
|
€ 0.122
|
|
€ 0.122
|
Common stock, shares authorized |
52,549,354
|
|
52,549,354
|
|
Common stock, shares issued |
40,498,764
|
|
40,191,264
|
|
Common stock, shares outstanding |
40,498,764
|
|
40,191,264
|
|
X |
- DefinitionA valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.4) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=49124121&loc=d3e5074-111524
+ Details
Name: |
us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionFace amount or stated value per share of common stock.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5
+ Details
Name: |
us-gaap_CommonStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5
+ Details
Name: |
us-gaap_CommonStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5
+ Details
Name: |
us-gaap_CommonStockSharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5
+ Details
Name: |
us-gaap_CommonStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
v3.3.1.900
Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands |
6 Months Ended |
Jun. 30, 2015 |
Jun. 30, 2014 |
Cash flows from operating activities: |
|
|
Net income (loss) |
$ (5,753)
|
$ (47,711)
|
Depreciation of property and equipment and intangible assets |
6,531
|
7,216
|
Gains on sales of marketable securities |
225
|
0
|
Grants recognized in other income and income from operations |
(1,086)
|
(337)
|
Remeasurement of acquisition liabilities |
37,256
|
30,246
|
Interest expenses on debt related to the royalty agreement including related party |
2,986
|
1,179
|
Unrealized exchange gains |
(7,315)
|
0
|
Stock compensation expense |
4,152
|
1,107
|
Income tax |
6,456
|
(2,807)
|
Increase (decrease) in cash from: |
|
|
Accounts receivable |
(1,015)
|
2,520
|
Inventory |
1,175
|
(1,816)
|
Prepaid expenses and other current assets |
(1,460)
|
(750)
|
Research and development tax credit receivable |
3,807
|
5,132
|
Accounts payable and Other Current Liabilities |
(3,265)
|
214
|
Deferred revenue |
(1,314)
|
(397)
|
Accrued expenses |
(2,138)
|
(1,847)
|
Other long-term assets and liabilities |
59
|
248
|
Net cash provided by (used in) operating activities |
39,301
|
(7,803)
|
Cash flows from investing activities: |
|
|
Purchases of property and equipment |
(659)
|
(712)
|
Purchase of marketable securities |
(31,093)
|
(27,752)
|
Proceeds from sales of marketable securities |
21,196
|
4,334
|
Net cash provided by (used in) investing activities |
(10,556)
|
(24,130)
|
Cash flows from financing activities: |
|
|
Repayment of Debt |
(5,791)
|
(34,471)
|
Reimbursment of conditional grants |
(615)
|
(151)
|
Earnout payments on acquisition related debt to related parties |
(6,118)
|
(611)
|
Proceeds from issuance of ordinary shares and warrants |
1,652
|
116,152
|
Net cash provided by (used in) financing activities |
(10,872)
|
80,919
|
Effect of exchange rate changes on cash and cash equivalents |
(2,397)
|
(1,518)
|
Net increase (decrease) in cash and cash equivalents |
15,476
|
47,468
|
Cash and cash equivalents, beginning of period |
39,760
|
6,636
|
Cash and cash equivalents, end of period |
55,236
|
54,104
|
Supplemental disclosures of cash flow information: |
|
|
Income tax paid |
20,875
|
281
|
Interest paid |
$ 1,367
|
$ 5,358
|
X |
- DefinitionThe cash outflow for earnout payments for acquisition.
+ References
+ Details
Name: |
flml_EarnoutPaymentsForAcquisition |
Namespace Prefix: |
flml_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe amount of grants recognized in other income and income from operations during the reporting period.
+ References
+ Details
Name: |
flml_GrantsRecognizedInOtherIncomeAndIncomeFromOperations |
Namespace Prefix: |
flml_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in research and development tax credit receivable.
+ References
+ Details
Name: |
flml_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable |
Namespace Prefix: |
flml_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionRepresents the remeasurement of acquisition liabilities and Royalty agreement.
+ References
+ Details
Name: |
flml_RemeasurementOfAcquisitionLiabilitiesAndRoyaltyAgreement |
Namespace Prefix: |
flml_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash Equivalents -URI http://asc.fasb.org/extlink&oid=6507016
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_CashAndCashEquivalentsAtCarryingValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 230 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906
+ Details
Name: |
us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_DepreciationDepletionAndAmortization |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 230 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906
+ Details
Name: |
us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in the aggregate amount of obligations incurred but not paid and other operating obligations not separately disclosed in the statement of cash flows.
+ References
+ Details
Name: |
us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_IncreaseDecreaseInAccountsReceivable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_IncreaseDecreaseInAccruedLiabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_IncreaseDecreaseInDeferredRevenue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_IncreaseDecreaseInInventories |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_IncreaseDecreaseInOperatingCapitalAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in other noncurrent operating assets less other noncurrent operating liabilities not separately disclosed in the statement of cash flows.
+ References
+ Details
Name: |
us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe amount of cash paid for interest during the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585
+ Details
Name: |
us-gaap_InterestPaid |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThis item represents the total realized gain (loss) included in earnings for the period as a result of selling marketable securities categorized as trading, available-for-sale, or held-to-maturity. Additionally, this item would include any losses recognized for other than temporary impairments (OTTI) of the subject investments in debt and equity securities.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.7(c)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 50 -Paragraph 9 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27357-111563
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 50 -Paragraph 10 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27405-111563
+ Details
Name: |
us-gaap_MarketableSecuritiesRealizedGainLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=51831255
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.19) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.18) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.22) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=51831270
Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5
Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585
+ Details
Name: |
us-gaap_PaymentsToAcquirePropertyPlantAndEquipment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585
+ Details
Name: |
us-gaap_ProceedsFromIssuanceOrSaleOfEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow associated with the sale of debt and equity securities classified as available-for-sale securities.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=49167202&loc=d3e26853-111562
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (a),(b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3179-108585
+ Details
Name: |
us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow attributable to repayments of borrowings not otherwise defined in the taxonomy (with maturities initially due after one year or beyond the operating cycle if longer).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228
+ Details
Name: |
us-gaap_RepaymentsOfOtherLongTermDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228
+ Details
Name: |
us-gaap_RepaymentsOfSecuredDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_ShareBasedCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of unrealized gain (loss) recognized in the income statement on unsold other securities.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_UnrealizedGainLossOnSecurities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
v3.3.1.900
Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands |
Total |
Common Stock [Member] |
Additional Paid-in Capital [Member] |
Retained Earnings [Member] |
Accumulated Other Comprehensive Income (Loss) [Member] |
Balance at Dec. 31, 2014 |
$ 24,895
|
$ 6,188
|
$ 346,581
|
$ (320,452)
|
$ (7,423)
|
Balance (in shares) at Dec. 31, 2014 |
|
40,191,264
|
|
|
|
Subscription of warrants |
0
|
|
|
|
|
Issuance of ordinary shares on exercise of stock or warrants |
1,652
|
$ 41
|
1,611
|
|
|
Issuance of ordinary shares on exercise of stock or warrants (in shares) |
|
307,500
|
|
|
|
Issuance of ordinary shares on Capital raise |
0
|
$ 0
|
0
|
|
|
Issuance of ordinary shares on Capital raise (in shares) |
|
0
|
|
|
|
Stock-based compensation expense |
4,231
|
|
4,231
|
|
|
Net loss |
(5,753)
|
|
|
(5,753)
|
|
Other comprehensive income (loss) |
(11,387)
|
|
|
|
(11,387)
|
Balance at Jun. 30, 2015 |
13,637
|
$ 6,229
|
352,423
|
(326,205)
|
(18,810)
|
Balance (in shares) at Jun. 30, 2015 |
|
40,498,764
|
|
|
|
Balance at Mar. 31, 2015 |
22,246
|
$ 6,196
|
348,571
|
(308,805)
|
(23,716)
|
Balance (in shares) at Mar. 31, 2015 |
|
40,253,014
|
|
|
|
Subscription of warrants |
0
|
|
|
|
|
Issuance of ordinary shares on exercise of stock or warrants |
1,405
|
$ 33
|
1,372
|
|
|
Issuance of ordinary shares on exercise of stock or warrants (in shares) |
|
245,750
|
|
|
|
Issuance of ordinary shares on Capital raise |
0
|
$ 0
|
0
|
|
|
Issuance of ordinary shares on Capital raise (in shares) |
|
0
|
|
|
|
Stock-based compensation expense |
2,480
|
|
2,480
|
|
|
Net loss |
(17,400)
|
|
|
(17,400)
|
|
Other comprehensive income (loss) |
4,906
|
|
|
|
4,906
|
Balance at Jun. 30, 2015 |
$ 13,637
|
$ 6,229
|
$ 352,423
|
$ (326,205)
|
$ (18,810)
|
Balance (in shares) at Jun. 30, 2015 |
|
40,498,764
|
|
|
|
X |
- DefinitionThe Number Of Shares Issued During The Period To Raise Capital
+ References
+ Details
Name: |
flml_StockIssuedDuringPeriodSharesOnCapitalRaise |
Namespace Prefix: |
flml_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of warrants exercised during the current period.
+ References
+ Details
Name: |
flml_StockIssuedDuringPeriodSharesWarrantExercised |
Namespace Prefix: |
flml_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionValue of shares of stock issued during the period as part of a transaction to raise capital.
+ References
+ Details
Name: |
flml_StockIssuedDuringPeriodValueOnCapitalRaise |
Namespace Prefix: |
flml_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionValue of stock issued as a result of the exercise of warrant.
+ References
+ Details
Name: |
flml_StockIssuedDuringPeriodValueWarrantExercised |
Namespace Prefix: |
flml_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 25 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=28183637&loc=d3e4724-112606
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Warrant -URI http://asc.fasb.org/extlink&oid=6528364
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5
+ Details
Name: |
us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=51831255
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.19) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.18) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.22) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=51831270
Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5
Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount after tax of other comprehensive income (loss) attributable to parent entity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1A -Subparagraph (c)(3) -URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 19 -URI http://asc.fasb.org/extlink&oid=51664549&loc=SL4569616-111683
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=51664549&loc=SL4569643-111683
+ Details
Name: |
us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares issued which are neither cancelled nor held in the treasury.
+ References
+ Details
Name: |
us-gaap_SharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionValue, after forfeitures, of stock or other type of equity granted of any equity-based compensation plan other than an employee stock ownership plan (ESOP).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 30 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=51830203&loc=d3e3913-113898
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 30 -Section 35 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6418191&loc=d3e15009-113911
+ Details
Name: |
us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E
+ Details
Name: |
us-gaap_StockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
|
6 Months Ended |
Jun. 30, 2015 |
Accounting Policies [Abstract] |
|
Significant Accounting Policies [Text Block] |
1. SUMMARY OF SIGNIFICANT accounting policies In the opinion of the management of Flamel Technologies S.A. (the “Company”), the accompanying unaudited, condensed, consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial statements. Accordingly, these Financial Statements do not include all of the information and footnotes required for complete annual financial statements, since certain footnotes and other financial information required by generally accepted accounting principles in the United States (or US GAAP) can be condensed or omitted for interim reporting requirements. In the opinion of management, all adjustments (consisting of only normal recurring accruals) considered necessary for a fair presentation of our financial position and operating results have been included. The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Operating results for the six-month ended June 30, 2015 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2015. These condensed consolidated interim financial statements should be read in conjunction with the Company's audited annual financial statements. The reporting currency of the Company and its wholly-owned subsidiaries is the U.S. dollar as permitted by the SEC for a foreign private issuer (S-X Rule 3-20(a)). All financial statement amounts of the Company and any other subsidiary for which the functional currency is the Euro or any other currency other than the U.S. dollar, are translated into U.S. dollar equivalents at exchange rates as follows: (1) asset and liability accounts at period-end rates, (2) income statement accounts at weighted average exchange rates for the period-end, and (3) shareholders' equity accounts at historical rates. Corresponding translation gains or losses are recorded in shareholders' equity. The Company followed the guidance in Financial Accounting Standards Board Accounting Standards Codification (“ASC”) Topic 205 Presentation of Financial Statements (ASC 205), Topic 360 Property, Plant and Equipment (ASC 360) and Accounting Standards Update (ASU 2014-08), Reporting of Discontinued Operations and Disclosures of Disposals of Components of an Entity in determining the accounting for the divestiture of the Pessac facility which occurred on December 1, 2014. Presenting the divestiture as a discontinued operation provides a better understanding of the results of the Company’s new strategy and in assessing the impact of the disposal on the ongoing operations of the entity. The results of discontinued operations, less income taxes, have been reported as a separate component of income in the statement of operations. The assets and liabilities of the discontinued operation have been reported separately in the asset and liability section, of the balance sheets for the periods presented therein. See note 4 below for a description of the facts and circumstances related to the disposal. Other comprehensive income includes currency translation adjustments and unrealized gains on marketable securities. For the six-month period ended June 30, 2015 it represents a loss of $11.4 million. In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers.” The standard requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The standard will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective and permits the use of either the retrospective or cumulative effect transition method. The ASU was originally effective for annual and interim periods beginning after December 15, 2016; however, on July 9, 2015, the FASB decided to defer by one year the effective date of the ASU. As a result, the standard will be effective for annual and interim periods beginning after December 15, 2017. The Company has not yet selected a transition method and is evaluating the impact the adoption will have on its consolidated financial statements and related disclosures.
|
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for all significant accounting policies of the reporting entity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18861-107790
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18726-107790
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18743-107790
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18854-107790
+ Details
Name: |
us-gaap_SignificantAccountingPoliciesTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
REVENUES
|
6 Months Ended |
Jun. 30, 2015 |
Revenue Recognition Disclosure [Abstract] |
|
Revenue Recognition Disclosure [Text Block] |
2. REVENUES 2.1 Product sales and services Revenue is generally recognized when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the seller’s price to the buyer is fixed or determinable, and collectability is reasonably assured. The Company records revenue from product sales when title and risk of ownership have been transferred to the customer, which is typically upon delivery to the customer, and when the selling price is determinable. As is customary in the pharmaceutical industry, the Company’s gross product sales are subject to a variety of deductions in arriving at reported net product sales. When the Company recognizes revenue from the sale of its products, an estimate of provision for sales returns and allowances is recorded which reduces product sales. These deductions include estimates for product returns, chargebacks, payment discounts and other sales allowances and rebates. The estimate for chargebacks is determined when product is shipped from the wholesalers to their customers. The return allowance, when estimable, is based on an analysis of the historical returns of the product or similar products. For generic products and branded products sold in mature and stable markets where changes in selling price are rare, the Company recognizes revenues upon shipment. For branded products where market conditions remain volatile and selling price is subject to change the Company recognizes revenue based on net product sales of wholesalers to their customers. For new product launches the Company recognizes revenue once sufficient data is available to determine product acceptance in the marketplace such that product returns may be estimated based on historical data and there is evidence of reorders and consideration is made of wholesaler inventory levels. Net product sales of wholesalers to their customers are determined using sales data from an independent wholesaler inventory tracking service. Net sales of wholesalers to their customers are calculated by deducting estimates for returns for wholesaler customers, chargebacks, payment discounts and other sales or discounts offered from the applicable gross sales value. Estimates for product returns are adjusted periodically based upon historical rates of returns, inventory levels in the distribution channel and other related factors. The Company recognized net product sales of $82.5 million for the first six-month of 2015 compared to $6.4 million for the six-month period ended June 30, 2014. Branded product sales are generated on sales from wholesalers to hospitals of Bloxiverz® and Vazculep®. Net product sales of wholesalers to their customers (hospitals) are determined using sales data from an independent wholesaler inventory tracking service and are calculated by deducting from the applicable gross sales value estimates for returns for wholesalers’ customers, chargebacks, early payment discounts and other sales or discounts offered.
|
X |
- References
+ Details
Name: |
flml_RevenueRecognitionDisclosureAbstract |
Namespace Prefix: |
flml_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for the license, research and consulting agreements that were made with the customers during the period.
+ References
+ Details
Name: |
flml_RevenueRecognitionDisclosureTextBlock |
Namespace Prefix: |
flml_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
RESEARCH TAX CREDIT
|
6 Months Ended |
Jun. 30, 2015 |
Research Tax Credit [Abstract] |
|
Research Tax Credit Disclosure [Text Block] |
3. RESEARCH TAX CREDIT The French government provides tax credits to companies for spending on innovative research and development. The research tax credit is considered as a grant and is deducted from operating expenses. For the six-month period ended June 30, 2015, the credit amounted to $1.6 million ($0.9 million for the three month period ended June 30, 2015) compared to $2.7 million for the six-month period ended June 30, 2014 ($1.3 million for the three month period ended June 30, 2014). The decrease reflects the reduction in R&D spending that is deemed eligible for the R&D tax credit in France.
|
X |
- References
+ Details
Name: |
flml_ResearchTaxCreditAbstract |
Namespace Prefix: |
flml_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure related to research tax credit.
+ References
+ Details
Name: |
flml_ResearchTaxCreditDisclosureTextBlock |
Namespace Prefix: |
flml_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
DISCONTINUED OPERATIONS
|
6 Months Ended |
Jun. 30, 2015 |
Discontinued Operations and Disposal Groups [Abstract] |
|
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] |
4. DISCONTINUED OPERATIONS On December 1, 2014, the Company signed an Asset Purchase Agreement with Recipharm for the divestiture of its development and manufacturing facility located in Pessac, France. The assets included in the divestiture were tangible equipment, furniture and fixtures, inventories and all intellectual property rights relating to the operation and technological know-how necessary in manufacturing the products that are produced in the facility and the assignment to Recipharm of all employees, customer contracts and liabilities which primarily relate to agreements of the Company with GlaxoSmithKline (“GSK”) for the manufacture and sale of Coreg CR®. Coreg CR® was Flamel’s lead product using the Micropump drug delivery platform that was developed with GSK and has been approved and sold in the US since 2007. The semi-finished product is manufactured in the Pessac Facility. The contracts assigned to Recipharm exclude the Amended 2003 License Agreement and 2004 License Agreement (collectively “License Agreements”) between Flamel and GSK for the development of Coreg CR®. However, the royalties to be earned by Flamel from the sales of Coreg CR® were transferred to Recipharm as part of the Asset Purchase Agreement. All costs and future revenues relating to the manufacture and sale of Coreg CR® were transferred to Recipharm. Royalties from Coreg CR® sales amounted to $3.6 million in the first half of 2014. Revenues from sales of Coreg CR® microparticles to GSK amounted to $3.5 million in the first half of 2014. Revenues from research revenues with undisclosed partners amounted to $1.6 million in the first half of 2014. The aggregate consideration the company received for the acquired assets and business was $13.2 million, plus the value of acquired inventory. All cash and receivables pertaining to Pessac Facility business prior to the sale were retained by Flamel. A contribution of $0.7 million was made to finance potential future retirement indemnities payable on transferred employees. The business was accounted for as a discontinued operation in the fourth quarter of 2014 and, therefore, the operating results of our Pessac Facility business were included in Discontinued Operations for the six-month period ended June 30, 2014. In connection with the Asset Purchase Agreement, the Company entered into a Master Agreement on Supply and Services of Products (“MSA”). Recipharm will provide various services in the domain of R&D and manufacture of pharmaceutical products for an initial non-cancellable period of five years for a minimum amount of services per year and for a cumulative total of $22.5 million. Over the initial term, any services to be provided to Flamel by Recipharm shall include internal and external costs incurred by Recipharm plus 20%, which has been determined to be fair value for such services. As of June 30, 2015 for the quarter ended, these services amounted to $1.1 million and for the six month period amounted to $2.4 million. Summary results of operations and major cash-flows for the Pessac business for the six and three month periods ended June 30, 2014 are detailed below. For the six and three month periods ended June 30, 2015 the Pessac business had no impact on results of operations or cash-flows other than in relation to contract manufacturing services in accordance with the “MSA” as discussed in the preceding paragraph : In thousands of U.S. Dollars | | Three months ended June 30, 2014 | | Six months ended June 30, 2014 | | | | | | | | | | Revenues | | $ | 4,318 | | $ | 8,896 | | Income (loss) from operations | | | (873) | | | (650) | | Income (loss) from discontinued operations, net of tax | | $ | (873) | | $ | (650) | | In thousands of U.S. Dollars | | Three months ended June 30, 2014 | | Six months ended June 30, 2014 | | Capital Expenditures | | $ | 317 | | $ | 631 | | | | | | | | | | Depreciation and Amortization | | | 517 | | | 1,033 | | | | | | | | | | Operating and investing non-cash elements | | | (186) | | | (347) | |
|
X |
- References
+ Details
Name: |
us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=51716988&loc=SL51721533-107759
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 4B -URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721665-107760
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 5C -URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721675-107760
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 3A -URI http://asc.fasb.org/extlink&oid=51719941&loc=SL51724579-110230
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 4A -URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721663-107760
Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=51719941&loc=d3e2941-110230
Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=51717284&loc=d3e1361-107760
Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 5B -URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721673-107760
Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 3A -URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721659-107760
Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 5A -URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721671-107760
Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 5D -URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721677-107760
Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=51717284&loc=d3e1474-107760
Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721683-107760
+ Details
Name: |
us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
X |
- References
+ Details
Name: |
us-gaap_StockholdersEquityNoteAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(d),(e)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 4 -Subparagraph (SAB TOPIC 4.C) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770
Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644
Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656
Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644
Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Preferred Stock -URI http://asc.fasb.org/extlink&oid=6521494
Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644
Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E
Reference 15: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section C
+ Details
Name: |
us-gaap_StockholdersEquityNoteDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
X |
- DefinitionThe entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 40 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 50 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=51659978&loc=d3e25284-112666
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901
Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 14
+ Details
Name: |
us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
INCOME TAX
|
6 Months Ended |
Jun. 30, 2015 |
Income Tax Disclosure [Abstract] |
|
Income Tax Disclosure [Text Block] |
7. INCOME TAX Income (loss) before income taxes comprises the following for the six-month period ended June 30, 2015: (in thousands of U.S. dollars) | | three months ended June 30, 2015 | | six months ended June 30, 2015 | | | | | | | | | | Ireland. | | $ | (11,278) | | $ | (16,317) | | France. | | | (1,123) | | | 9,113 | | United States.. | | | 5,242 | | | 22,166 | | Total. | | $ | (7,159) | | $ | 14,962 | | A reconciliation of income tax benefit (provision) computed at the French statutory rate (33.33%), Irish statutory rate (12.5%) and the US statutory rate (36.15%) to the actual income tax expense is as follows: (in thousands of U.S. dollars) | | Three months ended June 30, 2015 | | Six months ended June 30, 2015 | | | | | | | | | | Income tax benefit (provision) computed at the statutory rate | | $ | (115) | | $ | (9,011) | | Non Taxable remeasurement of fair value accounting of earn out | | | (11,568) | | | (13,467) | | Valuation allowance on operating losses in Ireland | | | (1,410) | | | (2,040) | | Other temporary and permanent differences | | | 2,851 | | | 3,803 | | Total | | $ | (10,242) | | $ | (20,715) | | In accordance with ASC 740-270, Interim Reporting, the tax provision for the six months ended June 30, 2015 is computed using an estimated annual effective tax rate of 31%. This is applied to income before tax, excluding losses from Irish operations, since no benefit is anticipated to be recognized on net operating loss carry forwards for the current fiscal year and items for which a reliable estimate cannot be made. The income tax provision as of June 30, 2015 amounts to $20.7 million.
|
X |
- DefinitionThe entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(h)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319
+ Details
Name: |
us-gaap_IncomeTaxDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
INTANGIBLE ASSETS
|
6 Months Ended |
Jun. 30, 2015 |
Goodwill and Intangible Assets Disclosure [Abstract] |
|
Goodwill and Intangible Assets Disclosure [Text Block] |
8. INTANGIBLE ASSETS | | December 31, | | June 30, | | | | 2014 | | 2015 | | (In thousands of U.S. dollars) | | Gross carrying amount | | Accumulated amortization | | Impairment | | Intangible assets, net | | Gross carrying amount | | Accumulated amortization | | Impairment | | Intangible assets, net | | | | | | | | | | | | | | | | | | | | - | | | | | | | | Intangible asset corresponding to acquired IPR&D of Bloxiverz | | | 35,248 | | | (11,749) | | | | | | 23,499 | | | 35,248 | | | (17,623) | | | | | | 17,625 | | Intangible asset corresponding to acquired IPR&D of Vazculep | | | 12,061 | | | - | | | (7,170) | | | 4,891 | | | 12,061 | | | (408) | | | (7,170) | | | 4,483 | | Total Intangible assets | | $ | 47,309 | | $ | (11,749) | | $ | (7,170) | | $ | 28,390 | | $ | 47,309 | | $ | (18,031) | | $ | (7,170) | | $ | 22,108 | | Intangible assets corresponding to acquired in-process R&D of Bloxiverz are being amortized on a straight-line basis over a 3 year period beginning January 1, 2014. Intangible assets corresponding to acquired in-process R&D of Vazculep are amortized on a straight-line period over 6-years beginning January 1, 2015.
|
X |
- References
+ Details
Name: |
us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16373-109275
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13854-109267
+ Details
Name: |
us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
INVENTORY
|
6 Months Ended |
Jun. 30, 2015 |
Inventory Disclosure [Abstract] |
|
Inventory Disclosure [Text Block] |
9. INVENTORY Inventories consist of raw materials and finished products, which are stated at cost determined under the first-in, first-out ("FIFO") method. Raw materials used in the production of pre-clinical and clinical products are expensed as R&D costs when consumed. The Company establishes reserves for inventory estimated to be obsolete, unmarketable or slow-moving on a case by case basis. The components of inventories were as follows: (In thousands of U.S. dollars) | | December 31, 2014 | | June 30, 2015 | | | | | | | | | | Raw materials | | $ | 1,661 | | $ | 1,860 | | Finished goods. | | | 5,068 | | | 3,891 | | | | | | | | | | Inventories, net | | $ | 6,729 | | $ | 5,751 | |
|
X |
- References
+ Details
Name: |
us-gaap_InventoryDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.6) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 6 -Subparagraph a, b, c -Article 5
+ Details
Name: |
us-gaap_InventoryDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
LONG-TERM DEBT
|
6 Months Ended |
Jun. 30, 2015 |
Debt Disclosure [Abstract] |
|
Long-term Debt [Text Block] |
10. LONG-TERM DEBT Long-term debt comprises: (In thousands of U.S. dollars) | | December 31, 2014 | | June 30, 2015 | | | | | | | | | | Government loans for R&D projects (a) | | $ | 3,717 | | $ | 1,702 | | Acquisition liability contingent consideration (b) | | | 70,112 | | | 89,077 | | Acquisition liability warrant consideration (b) | | | 34,542 | | | 46,713 | | Deerfield Royalty agreement (c) | | | 6,837 | | | 8,256 | | Broadfin Royalty agreement (d) | | | 3,259 | | | 3,936 | | | | | | | | | | Total | | | 118,467 | | | 149,684 | | Current portion | | | 42,332 | | | 37,803 | | Long-term portion | | $ | 76,135 | | $ | 111,882 | | (a) French government agencies provide financing to French companies for research and development. At December 31, 2014 and June 30, 2015, the Company had outstanding loans of $3.7 million and $1.7 million, respectively for various programs. These loans do not bear interest and are repayable only in the event the research project is technically or commercially successful. Potential repayment is scheduled to occur from 2015 through 2019. In June 2015, the Company reimbursed $0.5 million in relation to a loan associated with a specific research project conducted from 2003 to 2005. In addition, the Company recognized a waiver for repayment of the remaining $1.1 million on the basis of limited commercial and technical success. The waiver is accounted for as a reduction to R&D expenses. (b) The Acquisition liability relates to the acquisition by the Company on March 13, 2012, through its wholly owned subsidiary Flamel US Holdings, Inc., or Flamel US, of all of the membership interests of Éclat Pharmaceuticals, LLC. In exchange for all of the issued and outstanding membership interests of Éclat Pharmaceuticals, Flamel US provided consideration consisting of: ⋅ | a $12 million senior, secured six-year note guaranteed by the Company and its subsidiaries and secured by the equity interests and assets of Éclat. The note was repaid in full on March 24, 2014 generating a loss of $3 million and accounted for in interest expense; | ⋅ | two warrants to purchase a total of 3,300,000 American Depositary Shares, each representing one ordinary share of Flamel (“ADSs”); and | ⋅ | a commitment to make earnout payments of 20% of any gross profit generated by certain Éclat Pharmaceuticals products. The Purchase Agreement also contains certain representations and warranties, covenants, indemnification and other customary provisions. | The fair value of the warrants was determined by using a Black-Scholes option pricing model with the following assumptions: | | December 31, 2014 | | June 30, 2015 | | Share price | | $ | 17.13 | | $ | 21.19 | | Risk-free interest rate | | | 1.17 | % | | 0.92 | % | Dividend yield | | | - | | | - | | Expected volatility | | | 56.5 | % | | 62.90 | % | Expected term | | | 3.3 years | | | 2.8 years | | Pursuant to guidance of ASC 815-40-15-7(i), the Company determined that the Warrants issued in March 2012 as consideration for the acquisition of Éclat could not be considered as being indexed to the Company’s own stock, on the basis that the exercise price for the warrants is determined in U.S. dollars, although the functional currency of the Company is the Euro. The Company determined that these warrants should be accounted as a debt instrument. As of June 30, 2015, the deferred consideration fair value was estimated by using a discounted cash flow model based on probability adjusted annual gross profit of each of the Éclat Pharmaceuticals products. This fair value measurement is based on significant inputs not observable in the market and thus represents a level 3 measurement as defined in ASC 820. The discount rate is 20%. (c) On February 4, 2013 the Company concluded a $15 million debt financing transaction (Facility Agreement) with Deerfield Management a current shareholder. The consideration received was as follows: ⋅ | $12.4 million for a facility agreement of a nominal value of $15 million, including a premium on reimbursement of $2.6 million. The indebtedness was repaid on March 24, 2014 in its entirety, the accelerated reimbursement of this note resulted in interest expenses of $2.5 million; | ⋅ | $2.6 million for a Royalty Agreement whereby, the Company’s wholly owned subsidiary Éclat subject to required regulatory approvals and launch of product, is to pay a 1.75% Royalty of the net sales of certain products sold by Éclat and any of its affiliates until December 31, 2024. | The fair value of the Royalty was estimated using a probability-weighted discounted cash flow model based on probability adjusted projected annual net sales of each of the products which may be approved and sold by Éclat Pharmaceuticals. This fair value measurement is based on significant inputs not observable in the market and thus represents a level 3 measurement as defined in ASC 820. The discount rate used is 20%. (d) On December 3, 2013 the Company concluded with Broadfin Healthcare Master Fund, a current shareholder, a $15 million debt financing transaction (Facility Agreement) divided in 3 tranches of $5 million each, Under the terms of the Facility, upon closing Broadfin made an initial loan of $5.0 million. Consideration received was as follows: ⋅ | $2.8 million for a Facility agreement of a nominal value of $5.0 million. Loans under the Facility were scheduled to mature upon the earlier to occur of (i) January 31, 2017 and (ii) the repayment in full of all outstanding amounts under the Deerfield Facility, but in no event prior to November 15, 2015. The indebtedness was repaid on March 24, 2014 in its entirety, the accelerated reimbursement of this note resulted in interest expenses of $ 2.2 million; | ⋅ | $2.2 million for a Royalty agreement whereby, the Company’s wholly owned subsidiary Éclat subject to required regulatory approvals and launch of product, is to pay a 0.834% Royalty of the net sales of certain products sold by Éclat and any of its affiliates until December 31, 2024. | The fair value of the Royalty was estimated using a probability-weighted discounted cash flow model based on probability adjusted projected annual net sales of each of the products which may be approved and sold by Éclat Pharmaceuticals. This fair value measurement is based on significant inputs not observable in the market and thus represents a level 3 measurement as defined in ASC 820. The discount rate used is 20%. Total contingent and future payments on long-term debt for the next five years ending June 30 (assuming the various assumptions of the probability adjusted annual gross profit and revenues of each of the Éclat Pharmaceuticals products and, as it relates to government research loans, the underlying projects are commercially or technically successful for governmental research loans) are as follows: (In thousands of U.S. dollars) | | June 30, 2015 | | | | | | | | | | | | 2015 | | | 19,846 | | 2016 | | | 19,513 | | 2017 | | | 21,814 | | 2018 | | | 21,893 | | 2019 | | | 16,691 | | 2020 | | | 12,352 | | | | | | | | | | 112,109 | |
|
X |
- References
+ Details
Name: |
us-gaap_DebtDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for long-term debt.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_LongTermDebtTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
RELATED PARTY TRANSACTIONS
|
6 Months Ended |
Jun. 30, 2015 |
Related Party Transactions [Abstract] |
|
Related Party Transactions Disclosure [Text Block] |
11. RELATED PARTY TRANSACTIONS In March 2012, we acquired, through our wholly owned subsidiary Flamel US Holdings, all of the membership interests of Éclat from Éclat Holdings, an affiliate of Flamel’s largest shareholder Deerfield Capital L.P. The consideration consisted of a $12 million senior, secured six-year note that is guaranteed by us and our subsidiaries and secured by the equity interests and assets of Éclat, two warrants to purchase a total of 3,300,000 ADSs of Flamel and commitments to make earnout payments of 20% of any gross profit generated by certain Éclat products and 100% of the gross profit generated by our former product Hycet®, up to a maximum of $1 million, which we sold in 2013. The $12 million senior note was repaid in full in March 2014 using the net proceeds from our public sale of ADSs and the Hycet® asset was disposed of in November 2013. Upon closing of the acquisition, Mr. Anderson, the Chief Executive Officer of Éclat, was appointed Chief Executive Officer of Flamel. Mr. Anderson retains a minority interest in Éclat Holdings, (now renamed Breaking Stick Holdings, LLC), and does not have the ability to control this entity by virtue of his minority interest. The senior secured note was repaid in full in March 2014. On February 4, 2013, we entered into a Facility Agreement (the “Deerfield Facility”), through Flamel US with Deerfield Private Design Fund II, L.P. and Deerfield Private Design International II, L.P. (together, the “Deerfield Entities”) providing for debt financing of $15 million by the Deerfield Entities (the “Loan”). The loan was repaid in full in March 2014 using the net proceeds from our public sale of ADSs. In conjunction with our entry into the Deerfield Facility, Éclat entered into a Royalty Agreement with Horizon Santé FLML, Sarl and Deerfield Private Design Fund II, L.P., both affiliates of the Deerfield Entities (together, “Deerfield PDF/Horizon”). The Royalty Agreement provides for Éclat to pay Deerfield PDF/Horizon 1.75% of the net sales price of the products sold by us and any of our affiliates until December 31, 2024, with royalty payments accruing daily and paid in arrears for each calendar quarter during the term of the Royalty Agreement. We have also entered into a Security Agreement dated February 4, 2013 with Deerfield PDF/Horizon, whereby Deerfield PDF/Horizon was granted a security interest in the intellectual property and regulatory rights related to the products to secure the obligations of Éclat and Flamel US, including the full and prompt payment of royalties to Deerfield PDF/Horizon under the Royalty Agreement. On December 3, 2013, we and certain of our U.S. subsidiaries entered into a Facility Agreement (the “Broadfin Facility”) with Broadfin Healthcare Master Fund, Ltd. (“Broadfin”) providing for loans by Broadfin in an aggregate amount not to exceed $15.0 million. The loans under the Broadfin Facility and the obligations under the Royalty Agreement were secured by a first priority security interest in intellectual property associated with our Medusa technology and a junior lien on substantially all of the assets of the borrowers, which were previously pledged in connection with the Deerfield Facility, the Royalty Agreement and the notes issued in connection with the Éclat acquisition. Under the terms of the Broadfin Facility, upon closing Broadfin made an initial loan of $5.0 million and we had the ability to request, at any time prior to August 15, 2014, up to two additional loans in the amount of $5.0 million each, with funding subject to certain specified conditions. We had the ability to prepay the outstanding loans under the Broadfin Facility at any time, without prepayment penalty and the full $5.0 million outstanding was subsequently repaid using a portion of the net proceeds from our public sale of ADSs in March 2014. In connection with entering into the Broadfin Facility, we also entered into a Royalty Agreement with Broadfin, dated as of December 3, 2013 (the “Broadfin Royalty Agreement”). Pursuant to the Broadfin Royalty Agreement, we are required to pay a royalty of 0.834% on the net sales of certain products sold by Éclat Pharmaceuticals, LLC and any of its affiliates until December 31, 2024.
|
X |
- DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864
Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph b -Article 3A
+ Details
Name: |
us-gaap_RelatedPartyTransactionsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
FAIR VALUE OF FINANCIAL INSTRUMENTS
|
6 Months Ended |
Jun. 30, 2015 |
Fair Value Disclosures [Abstract] |
|
Fair Value Disclosures [Text Block] |
12. FAIR VALUE OF FINANCIAL INSTRUMENTS At December 31, 2014 and June 30, 2015, the carrying values of financial instruments such as cash and cash equivalents, trade receivables and payables, other receivables and accrued liabilities and the current portion of long-term debt approximated their market values, based on the short-term maturities of these instruments. The company calculates fair values for its marketable securities based on quoted market prices for identical assets and liabilities which represent Level 1 of the ASC 820-10 fair value hierarchy. At December 31, 2014 and June 30, 2015 the fair values of long-term debt and long-term receivables were comparable with their respective carrying values. The following table presents information about the Company securities based on quoted market prices for identical assets and liabilities for June 30, 2015 and indicates the fair value hierarchy of the valuation techniques utilized to determine such fair value. | | | | | | | | | | | | | | | | | six months ended June, 30 2015 | | | | | six months ended June,30 2014 | | | | Net Carrying | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Value as of | | Net Carrying | | | | | | | | | | | Operational Gain | | | | | | | | | | | | | | | | | | | December 31, | | Value as of | | | | | | | | | | | (losses) recognized in | | Financial Gain (losses) | | | | | Operational Gain (losses) | | Financial Gain (losses) | | | | | (in thousands of US Dollars) | | 2014 | | June 30, 2015 | | Fair Value Measured and Recorded Using | | earnings | | recognized in earnings | | Total | | recognized in earnings | | recognized in earnings | | Total | | | | | | | | | | Level 1 | | Level 2 | | Level 3 | | | | | | | | | | | | | | | | | | | | Assets | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Cash and cash equivalent | | | 39,760 | | | 55,236 | | | 55,236 | | | - | | | - | | | - | | | - | | | - | | | - | | | - | | | - | | Marketable securities | | | 53,074 | | | 60,884 | | | 60,884 | | | - | | | - | | | - | | | 659 | | | 659 | | | - | | | - | | | - | | Total | | | | | | | | | | | | - | | | - | | | - | | | 659 | | | 659 | | | | | | | | | | | | | | | | | | | | | | | | | | | | six months ended June, 30 2015 | | six months ended June,30 2014 | | | | | | | | | | | | | | | | | | | Operational Gain | | Financial Gain (losses) | | | | | Operational Gain (losses) | | Financial Gain (losses) | | | | | | | Net Carrying | | Net Carrying | | | | | | | | | | | (losses) recognized in | | recognized in earnings | | | | | recognized in earnings | | recognized in earnings | | | | | | | Value as of | | Value as of | | | | | | | | | | | earnings "Fair Value | | "Interest expense on | | | | | "Fair Value | | "Interest expense on debt | | | | | | | December 31, | | June 30, | | | | | | | | | | | remeasurement of | | debt related to the | | | | | remeasurement of | | related to the royalty | | | | | (in thousands of US Dollars) | | 2014 | | 2015 | | Fair Value Measured and Recorded Using | | Acquisition liabilities" | | royalty agreement " | | Total | | Acquisition liabilities" | | agreement " | | Total | | | | | | | | | | Level 1 | | Level 2 | | Level 3 | | | | | | | | | | | | | | | | | | | | Liabilities | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Acquisition liability contingent consideration (a) | | | 70,112 | | | 89,077 | | | - | | | - | | | 89,077 | | | (25,083) | | | - | | | (25,083) | | | (8,862) | | | | | | (8,862) | | Acquisition liability note (b). | | | - | | | - | | | - | | | - | | | - | | | | | | | | | - | | | (3,013) | | | | | | (3,013) | | Acquisition liability warrant consideration (c) | | | 34,542 | | | 46,713 | | | - | | | - | | | 46,713 | | | (12,171) | | | - | | | (12,171) | | | (18,371) | | | - | | | (18,371) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Deerfield Royalty Agreement (d) | | | 6,837 | | | 8,256 | | | | | | | | | 8,256 | | | | | | (2,021) | | | (2,021) | | | | | | (836) | | | (836) | | Broadfin Royalty Agreement (d) | | | 3,259 | | | 3,936 | | | | | | | | | 3,936 | | | | | | (964) | | | (964) | | | - | | | (399) | | | (399) | | Total | | | 114,750 | | | 147,982 | | | | | | | | | 147,982 | | | (37,254) | | | (2,985) | | | (40,239) | | | (30,246) | | | (1,235) | | | (31,481) | | The fair values of the financial instruments in connection with the acquisition of Éclat (see note 10 Long-Term Debt) are estimated as follows: (a) Acquisition liability contingent consideration: the fair value is estimated using a discounted cash flow model based on probability adjusted projected annual gross profit of each of the products which formed the project portfolio at the time of acquisition of Éclat Pharmaceuticals (Note 10 Long Term Debt). The fair value of the contingent consideration will change over time in accordance with the changes in market conditions and business plan projections as it relates to market size, market share, product pricing, competitive landscape, and gross profit margins expected for each of the products. (b) Acquisition liability Note: the Company uses a probability-weighted discounted cash flow model (see note 10 Long Term Debt). The note was repaid on March 24, 2014. (c) Acquisition liability warrant consideration: the Company uses a Black-Scholes option pricing model. The fair value of the warrant consideration will change over time depending on the volatility and share price at balance sheet date (see note 10 Long Term Debt). (d) Broadfin and Deerfield Royalty Agreement: the fair value is estimated using a discounted cash flow model based on probability adjusted projected annual net sales of each of the products which may be approved and sold by Éclat Pharmaceuticals (Note 10 Long Term Debt). The discount rate used is 20%. The following tables provide a reconciliation of fair value for which the Company used Level 3 inputs: (in thousands of US Dollars) | | Acquisition | | | | Liabilities | | Liability recorded upon acquisition | | $ | (50,927) | | Operational gain (loss) recognized in earnings for fiscal year 2012 & 2013 | | | (9,142) | | Payment deferred consideration (Hycet) & interest on acquisition liability note. | | | 1,176 | | Net carrying value at January 1, 2014. | | | (58,893) | | Operational gain (loss) recognized in earnings for fiscal year 2014... | | | (60,503) | | Reimbursment of acquisition liability note. | | | 12,000 | | Payment of interest on acquisition liability note.. | | | 1,389 | | Payment of deferred consideration. | | | 1,354 | | | | | | | Net carrying value at January 1, 2015. | | | (104,653) | | Fair value remeasurement recognized in earnings for six months to June 30, 2015 | | | (37,254) | | Payment of deferred consideration. | | | 6,117 | | Net carrying value at June 30, 2015 | | $ | (135,791) | | (in thousands of US Dollars) | | Deerfield Royalty | | Broadfin Royalty | | | | Agreement | | Agreement | | Liability recorded upon execution of Agreeement | | $ | (2,600) | | $ | (2,187) | | Interest expense recognized in earnings for 2013 | | | (1,990) | | | | | Interest expense recognized in earnings for 2014 | | | (2,386) | | | (1,139) | | Payment of Royalty 2014 | | | 140 | | | 67 | | Net carrying value at Jan 1, 2015 | | | (6,837) | | | (3,259) | | Interest expense recognized in earnings for 6 months to June 30, 2015 | | | (2,021) | | | (964) | | Payment of Royalty | | | 601 | | | 287 | | Net carrying value at June 30, 2015 | | $ | (8,257) | | $ | (3,936) | | The acquisition liabilities, consisting of the warrants and deferred consideration, and Royalty agreement all of which are classified as long-term debt, are measured at fair value and the income or expense may change significantly as assumptions regarding the valuations and probability of successful development and approval of products in development vary.
|
X |
- References
+ Details
Name: |
us-gaap_FairValueDisclosuresAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 16 -URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13504-108611
Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13433-108611
+ Details
Name: |
us-gaap_FairValueDisclosuresTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
SUBSEQUENT EVENTS
|
6 Months Ended |
Jun. 30, 2015 |
Subsequent Events [Abstract] |
|
Subsequent Events [Text Block] |
13. Subsequent events The Company determines the fair value of contingent consideration and royalty agreements, classified as long term debt, by reference to a probability-weighted discounted cash flow model. The model changes over time as a result of changes in market conditions and including market size, market share, product pricing, competitive landscape, and gross profit margins expected for each of the products. Subsequent to June 30, 2015 the Company received acceptance from the FDA of its third NDA filing and observed changes in market conditions related to price increases implemented on competitor products and related to market share. Such events occurring subsequent to the balance sheet date have modified business plan projections and corresponding cash flows, which has resulted in a corresponding increase in the fair value of contingent consideration and royalty agreements of $56.0 million to reach $146.6 million as of September 30, 2015. The Company is evaluating the financial impact of events occurring subsequent to September 30, 2015 on the fair value of contingent consideration and royalty agreements.
|
X |
- References
+ Details
Name: |
us-gaap_SubsequentEventsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
+ Details
Name: |
us-gaap_SubsequentEventsTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
X |
- References
+ Details
Name: |
flml_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationCashFlowsTableTextBlock |
Namespace Prefix: |
flml_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of disposal groups, which may include the gain (loss) recognized in the income statement.
+ References
+ Details
Name: |
flml_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationIncomeStatementTableTextBlock |
Namespace Prefix: |
flml_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
INCOME TAX (Tables)
|
6 Months Ended |
Jun. 30, 2015 |
Income Tax Disclosure [Abstract] |
|
Schedule Of Components Of Income Before Income Tax [Table Text Block] |
Income (loss) before income taxes comprises the following for the six-month period ended June 30, 2015: (in thousands of U.S. dollars) | | three months ended June 30, 2015 | | six months ended June 30, 2015 | | | | | | | | | | Ireland. | | $ | (11,278) | | $ | (16,317) | | France. | | | (1,123) | | | 9,113 | | United States.. | | | 5,242 | | | 22,166 | | Total. | | $ | (7,159) | | $ | 14,962 | |
|
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] |
A reconciliation of income tax benefit (provision) computed at the French statutory rate (33.33%), Irish statutory rate (12.5%) and the US statutory rate (36.15%) to the actual income tax expense is as follows: (in thousands of U.S. dollars) | | Three months ended June 30, 2015 | | Six months ended June 30, 2015 | | | | | | | | | | Income tax benefit (provision) computed at the statutory rate | | $ | (115) | | $ | (9,011) | | Non Taxable remeasurement of fair value accounting of earn out | | | (11,568) | | | (13,467) | | Valuation allowance on operating losses in Ireland | | | (1,410) | | | (2,040) | | Other temporary and permanent differences | | | 2,851 | | | 3,803 | | Total | | $ | (10,242) | | $ | (20,715) | |
|
X |
- DefinitionTabular disclosure of components of income before income tax.
+ References
+ Details
Name: |
flml_ScheduleOfComponentsOfIncomeBeforeIncomeTaxTableTextBlock |
Namespace Prefix: |
flml_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319
+ Details
Name: |
us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
INTANGIBLE ASSETS (Tables)
|
6 Months Ended |
Jun. 30, 2015 |
Goodwill and Intangible Assets Disclosure [Abstract] |
|
Schedule of Finite-Lived Intangible Assets [Table Text Block] |
| | December 31, | | June 30, | | | | 2014 | | 2015 | | (In thousands of U.S. dollars) | | Gross carrying amount | | Accumulated amortization | | Impairment | | Intangible assets, net | | Gross carrying amount | | Accumulated amortization | | Impairment | | Intangible assets, net | | | | | | | | | | | | | | | | | | | | - | | | | | | | | Intangible asset corresponding to acquired IPR&D of Bloxiverz | | | 35,248 | | | (11,749) | | | | | | 23,499 | | | 35,248 | | | (17,623) | | | | | | 17,625 | | Intangible asset corresponding to acquired IPR&D of Vazculep | | | 12,061 | | | - | | | (7,170) | | | 4,891 | | | 12,061 | | | (408) | | | (7,170) | | | 4,483 | | Total Intangible assets | | $ | 47,309 | | $ | (11,749) | | $ | (7,170) | | $ | 28,390 | | $ | 47,309 | | $ | (18,031) | | $ | (7,170) | | $ | 22,108 | |
|
X |
- References
+ Details
Name: |
us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275
+ Details
Name: |
us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
INVENTORY (Tables)
|
6 Months Ended |
Jun. 30, 2015 |
Inventory Disclosure [Abstract] |
|
Schedule of Inventory, Current [Table Text Block] |
The components of inventories were as follows: (In thousands of U.S. dollars) | | December 31, 2014 | | June 30, 2015 | | | | | | | | | | Raw materials | | $ | 1,661 | | $ | 1,860 | | Finished goods. | | | 5,068 | | | 3,891 | | | | | | | | | | Inventories, net | | $ | 6,729 | | $ | 5,751 | |
|
X |
- References
+ Details
Name: |
us-gaap_InventoryDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 2 -Paragraph 6 -Subparagraph a,b,c -Article 5
+ Details
Name: |
us-gaap_ScheduleOfInventoryCurrentTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
LONG-TERM DEBT (Tables)
|
6 Months Ended |
Jun. 30, 2015 |
Debt Disclosure [Abstract] |
|
Schedule of Long-term Debt Instruments [Table Text Block] |
Long-term debt comprises: (In thousands of U.S. dollars) | | December 31, 2014 | | June 30, 2015 | | | | | | | | | | Government loans for R&D projects (a) | | $ | 3,717 | | $ | 1,702 | | Acquisition liability contingent consideration (b) | | | 70,112 | | | 89,077 | | Acquisition liability warrant consideration (b) | | | 34,542 | | | 46,713 | | Deerfield Royalty agreement (c) | | | 6,837 | | | 8,256 | | Broadfin Royalty agreement (d) | | | 3,259 | | | 3,936 | | | | | | | | | | Total | | | 118,467 | | | 149,684 | | Current portion | | | 42,332 | | | 37,803 | | Long-term portion | | $ | 76,135 | | $ | 111,882 | | (a) French government agencies provide financing to French companies for research and development. At December 31, 2014 and June 30, 2015, the Company had outstanding loans of $3.7 million and $1.7 million, respectively for various programs. These loans do not bear interest and are repayable only in the event the research project is technically or commercially successful. Potential repayment is scheduled to occur from 2015 through 2019. In June 2015, the Company reimbursed $0.5 million in relation to a loan associated with a specific research project conducted from 2003 to 2005. In addition, the Company recognized a waiver for repayment of the remaining $1.1 million on the basis of limited commercial and technical success. The waiver is accounted for as a reduction to R&D expenses. (b) The Acquisition liability relates to the acquisition by the Company on March 13, 2012, through its wholly owned subsidiary Flamel US Holdings, Inc., or Flamel US, of all of the membership interests of Éclat Pharmaceuticals, LLC. In exchange for all of the issued and outstanding membership interests of Éclat Pharmaceuticals, Flamel US provided consideration consisting of: ⋅ | a $12 million senior, secured six-year note guaranteed by the Company and its subsidiaries and secured by the equity interests and assets of Éclat. The note was repaid in full on March 24, 2014 generating a loss of $3 million and accounted for in interest expense; | ⋅ | two warrants to purchase a total of 3,300,000 American Depositary Shares, each representing one ordinary share of Flamel (“ADSs”); and | ⋅ | a commitment to make earnout payments of 20% of any gross profit generated by certain Éclat Pharmaceuticals products. The Purchase Agreement also contains certain representations and warranties, covenants, indemnification and other customary provisions. | (c) On February 4, 2013 the Company concluded a $15 million debt financing transaction (Facility Agreement) with Deerfield Management a current shareholder. The consideration received was as follows: ⋅ | $12.4 million for a facility agreement of a nominal value of $15 million, including a premium on reimbursement of $2.6 million. The indebtedness was repaid on March 24, 2014 in its entirety, the accelerated reimbursement of this note resulted in interest expenses of $2.5 million; | ⋅ | $2.6 million for a Royalty Agreement whereby, the Company’s wholly owned subsidiary Éclat subject to required regulatory approvals and launch of product, is to pay a 1.75% Royalty of the net sales of certain products sold by Éclat and any of its affiliates until December 31, 2024. | The fair value of the Royalty was estimated using a probability-weighted discounted cash flow model based on probability adjusted projected annual net sales of each of the products which may be approved and sold by Éclat Pharmaceuticals. This fair value measurement is based on significant inputs not observable in the market and thus represents a level 3 measurement as defined in ASC 820. The discount rate used is 20%. (d) On December 3, 2013 the Company concluded with Broadfin Healthcare Master Fund, a current shareholder, a $15 million debt financing transaction (Facility Agreement) divided in 3 tranches of $5 million each, Under the terms of the Facility, upon closing Broadfin made an initial loan of $5.0 million. Consideration received was as follows: ⋅ | $2.8 million for a Facility agreement of a nominal value of $5.0 million. Loans under the Facility were scheduled to mature upon the earlier to occur of (i) January 31, 2017 and (ii) the repayment in full of all outstanding amounts under the Deerfield Facility, but in no event prior to November 15, 2015. The indebtedness was repaid on March 24, 2014 in its entirety, the accelerated reimbursement of this note resulted in interest expenses of $ 2.2 million; | ⋅ | $2.2 million for a Royalty agreement whereby, the Company’s wholly owned subsidiary Éclat subject to required regulatory approvals and launch of product, is to pay a 0.834% Royalty of the net sales of certain products sold by Éclat and any of its affiliates until December 31, 2024. | The fair value of the Royalty was estimated using a probability-weighted discounted cash flow model based on probability adjusted projected annual net sales of each of the products which may be approved and sold by Éclat Pharmaceuticals. This fair value measurement is based on significant inputs not observable in the market and thus represents a level 3 measurement as defined in ASC 820. The discount rate used is 20%.
|
Schedule Of Fair Value Assumptions Of Warrant [Table Text Block] |
The fair value of the warrants was determined by using a Black-Scholes option pricing model with the following assumptions: | | December 31, 2014 | | June 30, 2015 | | Share price | | $ | 17.13 | | $ | 21.19 | | Risk-free interest rate | | | 1.17 | % | | 0.92 | % | Dividend yield | | | - | | | - | | Expected volatility | | | 56.5 | % | | 62.90 | % | Expected term | | | 3.3 years | | | 2.8 years | |
|
Schedule of Maturities of Long-term Debt [Table Text Block] |
Total contingent and future payments on long-term debt for the next five years ending June 30 (assuming the various assumptions of the probability adjusted annual gross profit and revenues of each of the Éclat Pharmaceuticals products and, as it relates to government research loans, the underlying projects are commercially or technically successful for governmental research loans) are as follows: (In thousands of U.S. dollars) | | June 30, 2015 | | | | | | | | | | | | 2015 | | | 19,846 | | 2016 | | | 19,513 | | 2017 | | | 21,814 | | 2018 | | | 21,893 | | 2019 | | | 16,691 | | 2020 | | | 12,352 | | | | | | | | | | 112,109 | |
|
X |
- DefinitionTabular disclosure for fair value assumptions of warrants.
+ References
+ Details
Name: |
flml_ScheduleOfFairValueAssumptionsOfWarrantTableTextBlock |
Namespace Prefix: |
flml_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_DebtDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(e),(f)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400
Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644
Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644
Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399
Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399
Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644
+ Details
Name: |
us-gaap_ScheduleOfDebtInstrumentsTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601
+ Details
Name: |
us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)
|
6 Months Ended |
Jun. 30, 2015 |
Fair Value Disclosures [Abstract] |
|
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] |
The following table presents information about the Company securities based on quoted market prices for identical assets and liabilities for June 30, 2015 and indicates the fair value hierarchy of the valuation techniques utilized to determine such fair value. | | | | | | | | | | | | | | | | | six months ended June, 30 2015 | | | | | six months ended June,30 2014 | | | | Net Carrying | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Value as of | | Net Carrying | | | | | | | | | | | Operational Gain | | | | | | | | | | | | | | | | | | | December 31, | | Value as of | | | | | | | | | | | (losses) recognized in | | Financial Gain (losses) | | | | | Operational Gain (losses) | | Financial Gain (losses) | | | | | (in thousands of US Dollars) | | 2014 | | June 30, 2015 | | Fair Value Measured and Recorded Using | | earnings | | recognized in earnings | | Total | | recognized in earnings | | recognized in earnings | | Total | | | | | | | | | | Level 1 | | Level 2 | | Level 3 | | | | | | | | | | | | | | | | | | | | Assets | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Cash and cash equivalent | | | 39,760 | | | 55,236 | | | 55,236 | | | - | | | - | | | - | | | - | | | - | | | - | | | - | | | - | | Marketable securities | | | 53,074 | | | 60,884 | | | 60,884 | | | - | | | - | | | - | | | 659 | | | 659 | | | - | | | - | | | - | | Total | | | | | | | | | | | | - | | | - | | | - | | | 659 | | | 659 | | | | | | | | | | | | | | | | | | | | | | | | | | | | six months ended June, 30 2015 | | six months ended June,30 2014 | | | | | | | | | | | | | | | | | | | Operational Gain | | Financial Gain (losses) | | | | | Operational Gain (losses) | | Financial Gain (losses) | | | | | | | Net Carrying | | Net Carrying | | | | | | | | | | | (losses) recognized in | | recognized in earnings | | | | | recognized in earnings | | recognized in earnings | | | | | | | Value as of | | Value as of | | | | | | | | | | | earnings "Fair Value | | "Interest expense on | | | | | "Fair Value | | "Interest expense on debt | | | | | | | December 31, | | June 30, | | | | | | | | | | | remeasurement of | | debt related to the | | | | | remeasurement of | | related to the royalty | | | | | (in thousands of US Dollars) | | 2014 | | 2015 | | Fair Value Measured and Recorded Using | | Acquisition liabilities" | | royalty agreement " | | Total | | Acquisition liabilities" | | agreement " | | Total | | | | | | | | | | Level 1 | | Level 2 | | Level 3 | | | | | | | | | | | | | | | | | | | | Liabilities | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Acquisition liability contingent consideration (a) | | | 70,112 | | | 89,077 | | | - | | | - | | | 89,077 | | | (25,083) | | | - | | | (25,083) | | | (8,862) | | | | | | (8,862) | | Acquisition liability note (b). | | | - | | | - | | | - | | | - | | | - | | | | | | | | | - | | | (3,013) | | | | | | (3,013) | | Acquisition liability warrant consideration (c) | | | 34,542 | | | 46,713 | | | - | | | - | | | 46,713 | | | (12,171) | | | - | | | (12,171) | | | (18,371) | | | - | | | (18,371) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Deerfield Royalty Agreement (d) | | | 6,837 | | | 8,256 | | | | | | | | | 8,256 | | | | | | (2,021) | | | (2,021) | | | | | | (836) | | | (836) | | Broadfin Royalty Agreement (d) | | | 3,259 | | | 3,936 | | | | | | | | | 3,936 | | | | | | (964) | | | (964) | | | - | | | (399) | | | (399) | | Total | | | 114,750 | | | 147,982 | | | | | | | | | 147,982 | | | (37,254) | | | (2,985) | | | (40,239) | | | (30,246) | | | (1,235) | | | (31,481) | | The fair values of the financial instruments in connection with the acquisition of Éclat (see note 10 Long-Term Debt) are estimated as follows: (a) Acquisition liability contingent consideration: the fair value is estimated using a discounted cash flow model based on probability adjusted projected annual gross profit of each of the products which formed the project portfolio at the time of acquisition of Éclat Pharmaceuticals (Note 10 Long Term Debt). The fair value of the contingent consideration will change over time in accordance with the changes in market conditions and business plan projections as it relates to market size, market share, product pricing, competitive landscape, and gross profit margins expected for each of the products. (b) Acquisition liability Note: the Company uses a probability-weighted discounted cash flow model (see note 10 Long Term Debt). The note was repaid on March 24, 2014. (c) Acquisition liability warrant consideration: the Company uses a Black-Scholes option pricing model. The fair value of the warrant consideration will change over time depending on the volatility and share price at balance sheet date (see note 10 Long Term Debt). (d) Broadfin and Deerfield Royalty Agreement: the fair value is estimated using a discounted cash flow model based on probability adjusted projected annual net sales of each of the products which may be approved and sold by Éclat Pharmaceuticals (Note 10 Long Term Debt). The discount rate used is 20%.
|
Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block] |
The following tables provide a reconciliation of fair value for which the Company used Level 3 inputs: (in thousands of US Dollars) | | Acquisition | | | | Liabilities | | Liability recorded upon acquisition | | $ | (50,927) | | Operational gain (loss) recognized in earnings for fiscal year 2012 & 2013 | | | (9,142) | | Payment deferred consideration (Hycet) & interest on acquisition liability note. | | | 1,176 | | Net carrying value at January 1, 2014. | | | (58,893) | | Operational gain (loss) recognized in earnings for fiscal year 2014... | | | (60,503) | | Reimbursment of acquisition liability note. | | | 12,000 | | Payment of interest on acquisition liability note.. | | | 1,389 | | Payment of deferred consideration. | | | 1,354 | | | | | | | Net carrying value at January 1, 2015. | | | (104,653) | | Fair value remeasurement recognized in earnings for six months to June 30, 2015 | | | (37,254) | | Payment of deferred consideration. | | | 6,117 | | Net carrying value at June 30, 2015 | | $ | (135,791) | | (in thousands of US Dollars) | | Deerfield Royalty | | Broadfin Royalty | | | | Agreement | | Agreement | | Liability recorded upon execution of Agreeement | | $ | (2,600) | | $ | (2,187) | | Interest expense recognized in earnings for 2013 | | | (1,990) | | | | | Interest expense recognized in earnings for 2014 | | | (2,386) | | | (1,139) | | Payment of Royalty 2014 | | | 140 | | | 67 | | Net carrying value at Jan 1, 2015 | | | (6,837) | | | (3,259) | | Interest expense recognized in earnings for 6 months to June 30, 2015 | | | (2,021) | | | (964) | | Payment of Royalty | | | 601 | | | 287 | | Net carrying value at June 30, 2015 | | $ | (8,257) | | $ | (3,936) | |
|
X |
- References
+ Details
Name: |
us-gaap_FairValueDisclosuresAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of quantitative information about the inputs used in the fair value measurement of liabilities. This disclosure may include, but is not limited to, the fair value of the liability, valuation technique used to measure fair value, the inputs used to measure fair value, the ranges of the inputs, and the weighted averages of the inputs.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb) -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258
+ Details
Name: |
us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19190-110258
+ Details
Name: |
us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual) - USD ($) $ in Thousands |
3 Months Ended |
6 Months Ended |
Jun. 30, 2015 |
Jun. 30, 2014 |
Jun. 30, 2015 |
Jun. 30, 2014 |
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent, Total |
$ 4,906
|
$ (1,257)
|
$ (11,387)
|
$ (2,025)
|
X |
- DefinitionAmount after tax of other comprehensive income (loss) attributable to parent entity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1A -Subparagraph (c)(3) -URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 19 -URI http://asc.fasb.org/extlink&oid=51664549&loc=SL4569616-111683
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=51664549&loc=SL4569643-111683
+ Details
Name: |
us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
v3.3.1.900
REVENUES (Details Textual) - USD ($) $ in Thousands |
3 Months Ended |
6 Months Ended |
Jun. 30, 2015 |
Jun. 30, 2014 |
Jun. 30, 2015 |
Jun. 30, 2014 |
Product sales and services |
$ 49,795
|
$ 2,499
|
$ 82,521
|
$ 6,479
|
X |
- DefinitionAggregate revenue during the period from the sale of goods in the normal course of business and also from providing service for the goods.
+ References
+ Details
Name: |
flml_SalesRevenueGoodsAndServicesNet |
Namespace Prefix: |
flml_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
v3.3.1.900
v3.3.1.900
X |
- References
+ Details
Name: |
flml_DisposalGroupsIncludingDiscontinuedOperationIncomeStatementLineItems |
Namespace Prefix: |
flml_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 5B -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721673-107760
+ Details
Name: |
us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of revenue attributable to disposal group, including, but not limited to, discontinued operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 5B -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721673-107760
+ Details
Name: |
us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.12) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 5C -Subparagraph (b)(2) -URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721675-107760
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.14) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=51716988&loc=d3e1012-107759
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 45 -Paragraph 3B -URI http://asc.fasb.org/extlink&oid=51716988&loc=SL51721525-107759
Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 45 -Paragraph 3A -URI http://asc.fasb.org/extlink&oid=51716988&loc=SL51721523-107759
Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=51716988&loc=d3e957-107759
Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=51717284&loc=d3e1361-107760
Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 13 -Article 7
Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 15 -Article 5
+ Details
Name: |
us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
v3.3.1.900
X |
- DefinitionAmount of operating and investing non-cash elements allocated to disposal group, including a discontinued operation.
+ References
+ Details
Name: |
flml_DisposalGroupIncludingDiscontinuedOperationOperatingAndInvesting |
Namespace Prefix: |
flml_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
flml_DisposalsGroupIncludingDiscontinuedOperationCashFlowsLineItems |
Namespace Prefix: |
flml_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of capital expenditure attributable to discontinued operations.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 5B -Subparagraph (c)(2) -URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721673-107760
+ Details
Name: |
us-gaap_CapitalExpenditureDiscontinuedOperations |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of deprecation and amortization expense attributable to property, plant and equipment and intangible assets of discontinued operations.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 5B -Subparagraph (c)(2) -URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721673-107760
+ Details
Name: |
us-gaap_DepreciationAndAmortizationDiscontinuedOperations |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
v3.3.1.900
DISCONTINUED OPERATIONS (Details Textual) - USD ($) $ in Thousands |
3 Months Ended |
6 Months Ended |
Jun. 30, 2015 |
Jun. 30, 2014 |
Jun. 30, 2015 |
Jun. 30, 2014 |
Discontinued Operations [Line Items] |
|
|
|
|
Minimum Amount On Supply And Services Of Products |
$ 1,100
|
|
$ 2,400
|
$ 22,500
|
License and Research Revenue |
$ 0
|
$ 1,819
|
$ 0
|
2,417
|
Pessac Business [Member] |
|
|
|
|
Discontinued Operations [Line Items] |
|
|
|
|
Contribution For Potential Employee Obligations |
|
|
|
700
|
Proceeds from Divestiture of Businesses |
|
|
|
$ 13,200
|
Recipharm AB [Member] |
|
|
|
|
Discontinued Operations [Line Items] |
|
|
|
|
Percentage Of Margin On Costs Incurred On Services |
|
|
|
20.00%
|
Undisclosed Partners [Member] |
|
|
|
|
Discontinued Operations [Line Items] |
|
|
|
|
License and Research Revenue |
|
|
|
$ 1,600
|
Coreg Sales [Member] |
|
|
|
|
Discontinued Operations [Line Items] |
|
|
|
|
Other Revenue, Net |
|
|
|
3,500
|
Proceeds From Production Facilities |
|
|
|
$ 3,600
|
X |
- DefinitionAmount of contribution made to finance the potential retirement obligations payable on transferred employees.
+ References
+ Details
Name: |
flml_ContributionForPotentialEmployeeObligations |
Namespace Prefix: |
flml_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
flml_DiscontinuedOperationsLineItems |
Namespace Prefix: |
flml_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionRevenue earned during the period relating to licensing fees and research revenue.
+ References
+ Details
Name: |
flml_LicenseAndResearchRevenue |
Namespace Prefix: |
flml_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe minimum amount on supply and services of products recognized during the fiscal year.
+ References
+ Details
Name: |
flml_MinimumAmountOnSupplyAndServicesOfProducts |
Namespace Prefix: |
flml_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe percentage of margin on costs incurred for services.
+ References
+ Details
Name: |
flml_PercentageOfMarginOnCostsIncurredOnServices |
Namespace Prefix: |
flml_ |
Data Type: |
num:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCash received for production facilities during the current period.
+ References
+ Details
Name: |
flml_ProceedsFromProductionFacilities |
Namespace Prefix: |
flml_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionRevenues from the sale of other goods or rendering of other services, not elsewhere specified in the taxonomy; net of (reduced by) sales adjustments, returns, allowances, and discounts.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(a),(d)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_OtherSalesRevenueNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3179-108585
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133
+ Details
Name: |
us-gaap_ProceedsFromDivestitureOfBusinesses |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=flml_PessacBusinessMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=flml_RecipharmAbMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DeferredRevenueArrangementTypeAxis=flml_CoregSalesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
SHAREHOLDERS' EQUITY (Details Textual) - shares
|
6 Months Ended |
|
Jun. 30, 2015 |
Dec. 31, 2014 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period |
307,500
|
|
Common Stock, Shares, Outstanding |
40,498,764
|
40,191,264
|
X |
- DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5
+ Details
Name: |
us-gaap_CommonStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of share options (or share units) exercised during the current period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(2) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28,29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
INCOME TAX (Details) - USD ($) $ in Thousands |
3 Months Ended |
6 Months Ended |
Jun. 30, 2015 |
Jun. 30, 2014 |
Jun. 30, 2015 |
Jun. 30, 2014 |
Income Taxes [Line Items] |
|
|
|
|
Income (loss) before income taxes |
$ (7,158)
|
$ (20,063)
|
$ 14,962
|
$ (49,726)
|
Ireland [Member] |
|
|
|
|
Income Taxes [Line Items] |
|
|
|
|
Income (loss) before income taxes |
(11,278)
|
|
(16,317)
|
|
France [Member] |
|
|
|
|
Income Taxes [Line Items] |
|
|
|
|
Income (loss) before income taxes |
(1,123)
|
|
9,113
|
|
United States [Member] |
|
|
|
|
Income Taxes [Line Items] |
|
|
|
|
Income (loss) before income taxes |
$ 5,242
|
|
$ 22,166
|
|
X |
- Details
Name: |
us-gaap_StatementGeographicalAxis=country_IE |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementGeographicalAxis=country_FR |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementGeographicalAxis=country_US |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
INCOME TAX (Details 1) - USD ($) $ in Thousands |
3 Months Ended |
6 Months Ended |
Jun. 30, 2015 |
Jun. 30, 2014 |
Jun. 30, 2015 |
Jun. 30, 2014 |
Income Taxes [Line Items] |
|
|
|
|
Income tax benefit (provision) computed at the statutory rate |
$ (115)
|
|
$ (9,011)
|
|
Non Taxable remeasurement of fair value accounting of earn out |
(11,568)
|
|
(13,467)
|
|
Valuation allowance on operating losses in Ireland |
(1,410)
|
|
(2,040)
|
|
Other temporary and permanent differences |
2,851
|
|
3,803
|
|
Total |
$ (10,242)
|
$ (137)
|
$ (20,715)
|
$ 2,665
|
v3.3.1.900
INCOME TAX (Details Textual) $ in Millions |
6 Months Ended |
Jun. 30, 2015
USD ($)
|
Income Taxes [Line Items] |
|
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent |
31.00%
|
Discontinued Operation, Provision for Loss (Gain) on Disposal, Net of Tax |
$ 20.7
|
Effective Income Tax Rate Reconciliation, Percent, Total |
36.15%
|
FRANCE |
|
Income Taxes [Line Items] |
|
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent |
33.33%
|
IRELAND |
|
Income Taxes [Line Items] |
|
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent |
12.50%
|
X |
- DefinitionAmount after tax of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a discontinued operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=51716988&loc=d3e957-107759
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 45 -Paragraph 3B -URI http://asc.fasb.org/extlink&oid=51716988&loc=SL51721525-107759
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 5C -Subparagraph (b)(2) -URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721675-107760
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=51717284&loc=d3e1361-107760
+ Details
Name: |
us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementGeographicalAxis=country_FR |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementGeographicalAxis=country_IE |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
INTANGIBLE ASSETS (Details) - USD ($) $ in Thousands |
6 Months Ended |
12 Months Ended |
Jun. 30, 2015 |
Dec. 31, 2014 |
Finite-Lived Intangible Assets [Line Items] |
|
|
Gross carrying amount |
$ 47,309
|
$ 47,309
|
Accumulated amortization |
(18,031)
|
(11,749)
|
Impairment |
(7,170)
|
(7,170)
|
Intangible assets, net |
22,108
|
28,390
|
Research and Development In Process [Member] | Bloxiverz [Member] |
|
|
Finite-Lived Intangible Assets [Line Items] |
|
|
Gross carrying amount |
35,248
|
35,248
|
Accumulated amortization |
(17,623)
|
(11,749)
|
Intangible assets, net |
17,625
|
23,499
|
Research and Development In Process [Member] | Vazculep [Member] |
|
|
Finite-Lived Intangible Assets [Line Items] |
|
|
Gross carrying amount |
12,061
|
12,061
|
Accumulated amortization |
(408)
|
0
|
Impairment |
(7,170)
|
(7,170)
|
Intangible assets, net |
$ 4,483
|
$ 4,891
|
X |
- DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionThe amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16373-109275
+ Details
Name: |
us-gaap_ImpairmentOfIntangibleAssetsFinitelived |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=flml_ResearchAndDevelopmentInProcessMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TitleOfIndividualAxis=flml_BloxiverzMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TitleOfIndividualAxis=flml_VazculepMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
X |
- DefinitionUseful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetUsefulLife |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=flml_ResearchAndDevelopmentInProcessMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TitleOfIndividualAxis=flml_BloxiverzMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TitleOfIndividualAxis=flml_VazculepMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
X |
- DefinitionAmount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.6(a)(1)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_InventoryFinishedGoods |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_InventoryLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.6(a)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 330 -SubTopic 10 -Section 35 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=51655945&loc=d3e3927-108312
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
+ Details
Name: |
us-gaap_InventoryNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.6(a)(4)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_InventoryRawMaterials |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
v3.3.1.900
LONG-TERM DEBT (Details) - USD ($) $ in Thousands |
Jun. 30, 2015 |
Dec. 31, 2014 |
Total |
|
$ 149,684
|
$ 118,467
|
Current portion |
|
37,803
|
42,332
|
Long-term portion |
|
111,882
|
76,135
|
Government Loans For Research And Development Projects [Member] |
|
|
|
Total |
[1] |
1,702
|
3,717
|
Acquisition liability contingent consideration [Member] |
|
|
|
Total |
[2] |
89,077
|
70,112
|
Acquisition liability warrant consideration [Member] |
|
|
|
Total |
[2] |
46,713
|
34,542
|
Deerfield Royalty agreement [Member] |
|
|
|
Total |
[3] |
8,256
|
6,837
|
Broadfin Royalty agreement [Member] |
|
|
|
Total |
[4] |
$ 3,936
|
$ 3,259
|
|
|
X |
- DefinitionCarrying amount of long-term debt, net of unamortized discount or premium, including current and noncurrent amounts. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.16) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.16) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 20, 22 -Article 5
+ Details
Name: |
us-gaap_LongTermDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of long-term debt, after unamortized discount or premium, scheduled to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_LongTermDebtCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_LongTermDebtNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=flml_GovernmentLoansForResearchAndDevelopmentProjectsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=flml_AcquisitionLiabilityContingentConsiderationMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=flml_AcquisitionLiabilityWarrantConsiderationMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=flml_DeerfieldRoyaltyAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=flml_BroadfinRoyaltyAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
X |
- DefinitionExpected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258
+ Details
Name: |
us-gaap_FairValueAssumptionsExpectedDividendRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPeriod the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258
+ Details
Name: |
us-gaap_FairValueAssumptionsExpectedTerm |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionMeasure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258
+ Details
Name: |
us-gaap_FairValueAssumptionsExpectedVolatilityRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionRisk-free interest rate assumption used in valuing an instrument.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258
+ Details
Name: |
us-gaap_FairValueAssumptionsRiskFreeInterestRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPrice of a single share of a number of saleable stocks of a company.
+ References
+ Details
Name: |
us-gaap_SharePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
v3.3.1.900
X |
- DefinitionAmount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04.(a)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690
+ Details
Name: |
us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04.(a)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601
+ Details
Name: |
us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04.(a)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690
+ Details
Name: |
us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04.(a)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601
+ Details
Name: |
us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04.(a)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690
+ Details
Name: |
us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04.(a)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690
+ Details
Name: |
us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionIncluding both current and noncurrent portions, carrying amount as of the balance sheet date of other forms of debt not elsewhere specified in the taxonomy with initial maturities beyond one year or beyond the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19, 20, 22 -Article 5
+ Details
Name: |
us-gaap_OtherLongTermDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.3.1.900
LONG-TERM DEBT (Details Textual) - USD ($) $ in Thousands |
|
|
6 Months Ended |
12 Months Ended |
|
Dec. 03, 2013 |
Feb. 04, 2013 |
Jun. 30, 2015 |
Jun. 30, 2014 |
Dec. 31, 2014 |
Dec. 31, 2013 |
Mar. 31, 2012 |
Interest Expense |
|
|
$ 482
|
$ 5,552
|
|
|
|
Proceeds from Issuance of Long-term Debt |
|
|
1,700
|
|
$ 3,700
|
|
|
Debt Financing Facility Agreement Amount |
$ 5,000
|
$ 15,000
|
|
|
|
|
|
Research and Development Arrangement with Federal Government, Costs Incurred, Net |
|
|
500
|
|
|
|
|
Research and Development Arrangement with Federal Government, Customer Funding to Offset Costs Incurred |
|
|
1,100
|
|
|
|
|
Facility Agreement [Member] |
|
|
|
|
|
|
|
Fair Value Inputs, Discount Rate |
|
20.00%
|
|
|
|
|
|
Premium On Reimbursement |
|
$ 2,600
|
|
|
|
|
|
Interest Expense |
2,200
|
2,500
|
|
|
|
|
|
Debt Financing Facility Agreement Amount |
15,000
|
15,000
|
$ 15,000
|
|
|
|
|
Fund Raised From Debt Financing Facility |
2,800
|
12,400
|
|
|
|
|
|
Initial Loan Amount |
5,000
|
|
|
|
|
|
|
Additional Loan Amount |
5,000
|
|
|
|
|
|
|
Debt Financing Nominal Value |
$ 5,000
|
|
|
|
|
|
|
Debt Repayment Term |
Jan. 31, 2017
|
|
|
|
|
|
|
Royalty Agreement [Member] |
|
|
|
|
|
|
|
Fund Raised From Debt Financing Facility |
$ 2,200
|
$ 2,600
|
|
|
|
|
|
Long Term Debt Repayment Percentage |
0.834%
|
1.75%
|
|
|
|
|
|
Debt Repayment Term |
Dec. 31, 2024
|
Dec. 31, 2024
|
|
|
|
|
|
Broadfin Facility Agreement [Member] |
|
|
|
|
|
|
|
Debt Repayment Term |
|
Mar. 24, 2014
|
|
|
|
|
|
Eclat Pharmaceuticals [Member] |
|
|
|
|
|
|
|
Percentage Of Earn Out Payment |
|
|
20.00%
|
|
|
20.00%
|
|
Eclat Pharmaceuticals [Member] | Senior Secured Six Year Note [Member] |
|
|
|
|
|
|
|
Secured Debt |
|
|
$ 12,000
|
|
|
|
$ 12,000
|
Interest Expense |
|
|
$ 3,000
|
|
|
|
|
American Depository Shares [Member] |
|
|
|
|
|
|
|
Class of Warrant or Right, Number of Securities Called by Warrants or Rights |
|
|
3,300,000
|
|
|
|
|
X |
- DefinitionRepresents the amount of two additional loans made.
+ References
+ Details
Name: |
flml_AdditionalLoanAmount |
Namespace Prefix: |
flml_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionRepresents the amount of debt financing facility agreement.
+ References
+ Details
Name: |
flml_DebtFinancingFacilityAgreementAmount |
Namespace Prefix: |
flml_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionRepresents the amount of nominal value of debt facility as on the period.
+ References
+ Details
Name: |
flml_DebtFinancingNominalValue |
Namespace Prefix: |
flml_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionRepresents term of debt repayment in CCYY-MM-DD format.
+ References
+ Details
Name: |
flml_DebtRepaymentTerm |
Namespace Prefix: |
flml_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTotal amount of fund raised from debt financing agreement.
+ References
+ Details
Name: |
flml_FundRaisedFromDebtFinancingFacility |
Namespace Prefix: |
flml_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionRepresents the amount of initial loan made.
+ References
+ Details
Name: |
flml_InitialLoanAmount |
Namespace Prefix: |
flml_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionRepresents the percentage of debt repayment.
+ References
+ Details
Name: |
flml_LongTermDebtRepaymentPercentage |
Namespace Prefix: |
flml_ |
Data Type: |
num:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionRepresents the percentage of earn out payment.
+ References
+ Details
Name: |
flml_PercentageOfEarnOutPayment |
Namespace Prefix: |
flml_ |
Data Type: |
num:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionRepresents the amount of premium on reimbursement.
+ References
+ Details
Name: |
flml_PremiumOnReimbursement |
Namespace Prefix: |
flml_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(i)(2)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAmount of the cost of borrowed funds accounted for as interest expense.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.9) -URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details
Name: |
us-gaap_InterestExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228
+ Details
Name: |
us-gaap_ProceedsFromIssuanceOfLongTermDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe net amount of research and development costs incurred for a fixed-price, best-efforts research and development cost-sharing arrangement with the Federal Government.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 730 -Section 25 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433
+ Details
Name: |
us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe amount of customer funding recorded as an offset to costs incurred for a fixed-price, best-efforts research and development cost-sharing arrangement with the Federal Government.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 730 -Section 25 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433
+ Details
Name: |
us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionCarrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.16) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.16) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19, 20, 22 -Article 5
+ Details
Name: |
us-gaap_SecuredDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=flml_FacilityAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=flml_RoyaltyAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=flml_BroadfinFacilityAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_BusinessAcquisitionAxis=flml_EclatPharmaceuticalsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=flml_SeniorSecuredSixYearNoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=flml_AmericanDepositorySharesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
RELATED PARTY TRANSACTIONS (Details Textual) - USD ($) $ in Thousands |
|
|
1 Months Ended |
6 Months Ended |
12 Months Ended |
Dec. 03, 2013 |
Feb. 04, 2013 |
Mar. 31, 2014 |
Mar. 31, 2012 |
Jun. 30, 2015 |
Jun. 30, 2014 |
Dec. 31, 2013 |
Contingent Potential Cash Payment |
|
|
|
|
|
|
$ 1,000
|
Debt Financing Facility Agreement Amount |
$ 5,000
|
$ 15,000
|
|
|
|
|
|
Business Combination Commitment Percentage |
|
|
|
|
|
|
100.00%
|
Repayments of Secured Debt |
|
|
|
|
$ 5,791
|
$ 34,471
|
|
Royalty Agreement [Member] |
|
|
|
|
|
|
|
Long Term Debt Repayment Percentage |
0.834%
|
1.75%
|
|
|
|
|
|
Debt Repayment Term |
Dec. 31, 2024
|
Dec. 31, 2024
|
|
|
|
|
|
Facility Agreement [Member] |
|
|
|
|
|
|
|
Debt Financing Facility Agreement Amount |
$ 15,000
|
$ 15,000
|
|
|
$ 15,000
|
|
|
Line of Credit Facility, Maximum Borrowing Capacity |
15,000
|
|
|
|
|
|
|
Line Of Credit Facility Initial Loan |
5,000
|
|
|
|
|
|
|
Line Of Credit Facility Additional Loan |
$ 5,000
|
|
|
|
|
|
|
Debt Repayment Term |
Jan. 31, 2017
|
|
|
|
|
|
|
Eclat Pharmaceuticals [Member] |
|
|
|
|
|
|
|
Percentage Of Earn Out Payment |
|
|
|
|
20.00%
|
|
20.00%
|
Eclat Pharmaceuticals [Member] | Senior Secured Six Year Note [Member] |
|
|
|
|
|
|
|
Secured Debt |
|
|
|
$ 12,000
|
$ 12,000
|
|
|
Warrants Issued During Period Warrants New Issues |
|
|
|
3,300,000
|
|
|
|
Repayments of Secured Debt |
|
|
$ 12,000
|
|
|
|
|
X |
- DefinitionRepresents the percentage of gross profit which is a commitment to pay under business combination.
+ References
+ Details
Name: |
flml_BusinessCombinationCommitmentPercentage |
Namespace Prefix: |
flml_ |
Data Type: |
num:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of potential cash payments that could result from the contingent consideration arrangement.
+ References
+ Details
Name: |
flml_ContingentPotentialCashPayment |
Namespace Prefix: |
flml_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionRepresents the amount of debt financing facility agreement.
+ References
+ Details
Name: |
flml_DebtFinancingFacilityAgreementAmount |
Namespace Prefix: |
flml_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionRepresents term of debt repayment in CCYY-MM-DD format.
+ References
+ Details
Name: |
flml_DebtRepaymentTerm |
Namespace Prefix: |
flml_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAdditional loan amount under the credit facility.
+ References
+ Details
Name: |
flml_LineOfCreditFacilityAdditionalLoan |
Namespace Prefix: |
flml_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe initial loan amount under the credit facility.
+ References
+ Details
Name: |
flml_LineOfCreditFacilityInitialLoan |
Namespace Prefix: |
flml_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionRepresents the percentage of debt repayment.
+ References
+ Details
Name: |
flml_LongTermDebtRepaymentPercentage |
Namespace Prefix: |
flml_ |
Data Type: |
num:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionRepresents the percentage of earn out payment.
+ References
+ Details
Name: |
flml_PercentageOfEarnOutPayment |
Namespace Prefix: |
flml_ |
Data Type: |
num:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of new warrants issued during the period.
+ References
+ Details
Name: |
flml_WarrantsIssuedDuringPeriodWarrantsNewIssues |
Namespace Prefix: |
flml_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(b),22(b)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228
+ Details
Name: |
us-gaap_RepaymentsOfSecuredDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionCarrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.16) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.16) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19, 20, 22 -Article 5
+ Details
Name: |
us-gaap_SecuredDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=flml_RoyaltyAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=flml_FacilityAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_BusinessAcquisitionAxis=flml_EclatPharmaceuticalsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=flml_SeniorSecuredSixYearNoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) - USD ($) $ in Thousands |
6 Months Ended |
|
Jun. 30, 2015 |
Jun. 30, 2014 |
Dec. 31, 2014 |
ASSETS |
|
|
|
|
Marketable securities |
|
$ 60,884
|
|
$ 53,074
|
Operational Gain (losses) recognized in earnings |
|
37,254
|
$ 30,246
|
|
Financial Gain (losses) recognized in earnings |
|
659
|
(1,235)
|
|
Total |
|
(40,239)
|
(31,481)
|
|
Liabilities |
|
|
|
|
Acquisition liability contingent consideration |
|
147,982
|
|
114,750
|
Operational Gain (losses) recognized in earnings |
|
(37,254)
|
(30,246)
|
|
Financial Gain (losses) recognized in earnings |
|
659
|
(1,235)
|
|
Total |
|
(40,239)
|
(31,481)
|
|
Fair Value, Inputs, Level 3 [Member] |
|
|
|
|
Liabilities |
|
|
|
|
Acquisition liability contingent consideration |
|
147,982
|
|
|
Cash and Cash Equivalents [Member] |
|
|
|
|
ASSETS |
|
|
|
|
Cash and cash equivalent |
|
55,236
|
|
39,760
|
Operational Gain (losses) recognized in earnings |
|
0
|
0
|
|
Financial Gain (losses) recognized in earnings |
|
0
|
0
|
|
Total |
|
0
|
0
|
|
Liabilities |
|
|
|
|
Operational Gain (losses) recognized in earnings |
|
0
|
0
|
|
Financial Gain (losses) recognized in earnings |
|
0
|
0
|
|
Total |
|
0
|
0
|
|
Cash and Cash Equivalents [Member] | Fair Value, Inputs, Level 1 [Member] |
|
|
|
|
ASSETS |
|
|
|
|
Cash and cash equivalent |
|
55,236
|
|
|
Cash and Cash Equivalents [Member] | Fair Value, Inputs, Level 2 [Member] |
|
|
|
|
ASSETS |
|
|
|
|
Cash and cash equivalent |
|
0
|
|
|
Cash and Cash Equivalents [Member] | Fair Value, Inputs, Level 3 [Member] |
|
|
|
|
ASSETS |
|
|
|
|
Cash and cash equivalent |
|
0
|
|
|
Marketable Securities [Member] |
|
|
|
|
ASSETS |
|
|
|
|
Marketable securities |
|
60,884
|
|
53,074
|
Operational Gain (losses) recognized in earnings |
|
0
|
0
|
|
Financial Gain (losses) recognized in earnings |
|
659
|
0
|
|
Total |
|
659
|
0
|
|
Liabilities |
|
|
|
|
Operational Gain (losses) recognized in earnings |
|
0
|
0
|
|
Financial Gain (losses) recognized in earnings |
|
659
|
0
|
|
Total |
|
659
|
0
|
|
Marketable Securities [Member] | Fair Value, Inputs, Level 1 [Member] |
|
|
|
|
ASSETS |
|
|
|
|
Marketable securities |
|
60,884
|
|
|
Marketable Securities [Member] | Fair Value, Inputs, Level 2 [Member] |
|
|
|
|
ASSETS |
|
|
|
|
Marketable securities |
|
0
|
|
|
Marketable Securities [Member] | Fair Value, Inputs, Level 3 [Member] |
|
|
|
|
ASSETS |
|
|
|
|
Marketable securities |
|
0
|
|
|
Acquisition Liability Contingent Consideration [Member] |
|
|
|
|
ASSETS |
|
|
|
|
Operational Gain (losses) recognized in earnings |
[1] |
25,083
|
8,862
|
|
Financial Gain (losses) recognized in earnings |
[1] |
0
|
|
|
Total |
[1] |
(25,083)
|
(8,862)
|
|
Liabilities |
|
|
|
|
Acquisition liability contingent consideration |
[1] |
89,077
|
|
70,112
|
Operational Gain (losses) recognized in earnings |
[1] |
(25,083)
|
(8,862)
|
|
Financial Gain (losses) recognized in earnings |
[1] |
0
|
|
|
Total |
[1] |
(25,083)
|
(8,862)
|
|
Acquisition Liability Contingent Consideration [Member] | Fair Value, Inputs, Level 1 [Member] |
|
|
|
|
Liabilities |
|
|
|
|
Acquisition liability contingent consideration |
[1] |
0
|
|
|
Acquisition Liability Contingent Consideration [Member] | Fair Value, Inputs, Level 2 [Member] |
|
|
|
|
Liabilities |
|
|
|
|
Acquisition liability contingent consideration |
[1] |
0
|
|
|
Acquisition Liability Contingent Consideration [Member] | Fair Value, Inputs, Level 3 [Member] |
|
|
|
|
Liabilities |
|
|
|
|
Acquisition liability contingent consideration |
[1] |
89,077
|
|
|
Acquisition Liability Note [Member] |
|
|
|
|
ASSETS |
|
|
|
|
Operational Gain (losses) recognized in earnings |
[2] |
|
3,013
|
|
Total |
[2] |
0
|
(3,013)
|
|
Liabilities |
|
|
|
|
Acquisition liability contingent consideration |
[2] |
0
|
|
0
|
Operational Gain (losses) recognized in earnings |
[2] |
|
(3,013)
|
|
Total |
[2] |
0
|
(3,013)
|
|
Acquisition Liability Note [Member] | Fair Value, Inputs, Level 1 [Member] |
|
|
|
|
Liabilities |
|
|
|
|
Acquisition liability contingent consideration |
[2] |
0
|
|
|
Acquisition Liability Note [Member] | Fair Value, Inputs, Level 2 [Member] |
|
|
|
|
Liabilities |
|
|
|
|
Acquisition liability contingent consideration |
[2] |
0
|
|
|
Acquisition Liability Note [Member] | Fair Value, Inputs, Level 3 [Member] |
|
|
|
|
Liabilities |
|
|
|
|
Acquisition liability contingent consideration |
[2] |
0
|
|
|
Acquisition Liability Warrant Consideration [Member] |
|
|
|
|
ASSETS |
|
|
|
|
Operational Gain (losses) recognized in earnings |
[3] |
12,171
|
18,371
|
|
Financial Gain (losses) recognized in earnings |
[3] |
0
|
0
|
|
Total |
[3] |
(12,171)
|
(18,371)
|
|
Liabilities |
|
|
|
|
Acquisition liability contingent consideration |
[3] |
46,713
|
|
34,542
|
Operational Gain (losses) recognized in earnings |
[3] |
(12,171)
|
(18,371)
|
|
Financial Gain (losses) recognized in earnings |
[3] |
0
|
0
|
|
Total |
[3] |
(12,171)
|
(18,371)
|
|
Acquisition Liability Warrant Consideration [Member] | Fair Value, Inputs, Level 1 [Member] |
|
|
|
|
Liabilities |
|
|
|
|
Acquisition liability contingent consideration |
[3] |
0
|
|
|
Acquisition Liability Warrant Consideration [Member] | Fair Value, Inputs, Level 2 [Member] |
|
|
|
|
Liabilities |
|
|
|
|
Acquisition liability contingent consideration |
[3] |
0
|
|
|
Acquisition Liability Warrant Consideration [Member] | Fair Value, Inputs, Level 3 [Member] |
|
|
|
|
Liabilities |
|
|
|
|
Acquisition liability contingent consideration |
[3] |
46,713
|
|
|
Deerfield Royalty Agreement [Member] |
|
|
|
|
ASSETS |
|
|
|
|
Financial Gain (losses) recognized in earnings |
[4] |
(2,021)
|
(836)
|
|
Total |
[4] |
(2,021)
|
(836)
|
|
Liabilities |
|
|
|
|
Acquisition liability contingent consideration |
[4] |
8,256
|
|
6,837
|
Financial Gain (losses) recognized in earnings |
[4] |
(2,021)
|
(836)
|
|
Total |
[4] |
(2,021)
|
(836)
|
|
Deerfield Royalty Agreement [Member] | Fair Value, Inputs, Level 3 [Member] |
|
|
|
|
Liabilities |
|
|
|
|
Acquisition liability contingent consideration |
[4] |
8,256
|
|
|
Broadfin Royalty Agreement [Member] |
|
|
|
|
ASSETS |
|
|
|
|
Operational Gain (losses) recognized in earnings |
[4] |
|
0
|
|
Financial Gain (losses) recognized in earnings |
[4] |
(964)
|
(399)
|
|
Total |
[4] |
(964)
|
(399)
|
|
Liabilities |
|
|
|
|
Acquisition liability contingent consideration |
[4] |
3,936
|
|
$ 3,259
|
Operational Gain (losses) recognized in earnings |
[4] |
|
0
|
|
Financial Gain (losses) recognized in earnings |
[4] |
(964)
|
(399)
|
|
Total |
[4] |
(964)
|
$ (399)
|
|
Broadfin Royalty Agreement [Member] | Fair Value, Inputs, Level 3 [Member] |
|
|
|
|
Liabilities |
|
|
|
|
Acquisition liability contingent consideration |
[4] |
$ 3,936
|
|
|
|
|
X |
- DefinitionNet fair value, as of the acquisition date, of potential payments under the contingent consideration arrangement including cash and shares.
+ References
+ Details
Name: |
flml_BusinessAcquisitionContingentConsiderationNet |
Namespace Prefix: |
flml_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionRepresents the financial amount of gain (loss) derived from fair value hedges recognized in earnings in the period.
+ References
+ Details
Name: |
flml_FinancialGainLossOnFairValueHedgesRecognizedInEarnings |
Namespace Prefix: |
flml_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionRepresents the operational amount of gain (loss) derived from fair value hedges recognized in earnings in the period.
+ References
+ Details
Name: |
flml_OperationalGainLossOnFairValueHedgesRecognizedInEarnings |
Namespace Prefix: |
flml_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash Equivalents -URI http://asc.fasb.org/extlink&oid=6507016
+ Details
Name: |
us-gaap_CashAndCashEquivalentsFairValueDisclosure |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTotal amount of gain (loss) derived from fair value hedges recognized in earnings in the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4C -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624171-113959
+ Details
Name: |
us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=49167202&loc=d3e26626-111562
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.2) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_MarketableSecuritiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_InvestmentTypeAxis=us-gaap_CashAndCashEquivalentsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_InvestmentTypeAxis=flml_MarketableSecuritiesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=flml_AcquisitionLiabilityContingentConsiderationMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=flml_AcquisitionLiabilityNoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=flml_AcquisitionLiabilityWarrantConsiderationMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=flml_DeerfieldRoyaltyAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=flml_BroadfinRoyaltyAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
FAIR VALUE OF FINANCIAL INSTRUMENTS (Details 1) - USD ($) $ in Thousands |
6 Months Ended |
12 Months Ended |
Jun. 30, 2015 |
Jun. 30, 2014 |
Dec. 31, 2014 |
Dec. 31, 2013 |
Dec. 31, 2012 |
Operational gain (loss) recognized in earnings |
$ 37,256
|
$ 30,246
|
|
|
|
Fair Value, Inputs, Level 3 [Member] |
|
|
|
|
|
Liability recorded upon acquisition |
(104,653)
|
$ (58,893)
|
$ (58,893)
|
|
$ (50,927)
|
Operational gain (loss) recognized in earnings |
|
|
(60,503)
|
$ (9,142)
|
(9,142)
|
Payment of interest on acquisition liability note |
|
|
1,389
|
1,176
|
|
Reimbursement of acquisition liability note |
|
|
12,000
|
|
|
Payment of deferred consideration |
6,117
|
|
1,354
|
|
|
Fair value remeasurement recognized in earnings for six months to June 30, 2015 |
(37,254)
|
|
|
|
|
Net carrying value |
(135,791)
|
|
(104,653)
|
(58,893)
|
|
Deerfield Royalty Agreement [Member] | Fair Value, Inputs, Level 3 [Member] |
|
|
|
|
|
Liability recorded upon acquisition |
(6,837)
|
|
|
(2,600)
|
|
Interest expense recognized in earnings |
(2,021)
|
|
(2,386)
|
(1,990)
|
|
Payment of royalty |
601
|
|
140
|
|
|
Net carrying value |
(8,257)
|
|
(6,837)
|
|
(2,600)
|
Broadfin Royalty Agreement [Member] | Fair Value, Inputs, Level 3 [Member] |
|
|
|
|
|
Liability recorded upon acquisition |
(3,259)
|
|
|
$ (2,187)
|
|
Interest expense recognized in earnings |
(964)
|
|
(1,139)
|
|
|
Payment of royalty |
287
|
|
67
|
|
|
Net carrying value |
$ (3,936)
|
|
$ (3,259)
|
|
$ (2,187)
|
X |
- DefinitionRepresents the amount paid for reimbursement.
+ References
+ Details
Name: |
flml_PaymentForReimbursements |
Namespace Prefix: |
flml_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionRepresents the remeasurement of acquisition liabilities and Royalty agreement.
+ References
+ Details
Name: |
flml_RemeasurementOfAcquisitionLiabilitiesAndRoyaltyAgreement |
Namespace Prefix: |
flml_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of realized and unrealized gain (loss) included in earnings, which have arisen from the use of significant unobservable inputs (level 3) to measure fair value of assets, liabilities, and financial instruments classified in shareholders' equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258
+ Details
Name: |
us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585
+ Details
Name: |
us-gaap_PaymentsToAcquireBusinessesGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133
+ Details
Name: |
us-gaap_PaymentsToAcquireNotesReceivable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.3) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_RoyaltyExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=flml_DeerfieldRoyaltyAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=flml_BroadfinRoyaltyAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
X |
- DefinitionFair value of contingent consideration and royalty agreements that is classified in long term debt.
+ References
+ Details
Name: |
flml_ContingentConsiderationAndRoyaltyAgreementClassifiedAsLongtermDebtFairValue |
Namespace Prefix: |
flml_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of increase (decrease) in the fair value of right to a contingent consideration and royalty agreement.
+ References
+ Details
Name: |
flml_IncreaseDecreaseInContingentConsiderationAndRoyaltyAgreementFairValue |
Namespace Prefix: |
flml_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
Avadel Pharmaceuticals (NASDAQ:AVDL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Avadel Pharmaceuticals (NASDAQ:AVDL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024